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INTRODUCTION 
Hepatitis B virus (HBV) is one of the most common chronic viral infections in the 
world a potentially life – threatening liver infection (McMahon, 2009b). It is a 
major global health problem as it can cause chronic liver disease and chronic 
infection and puts people at high risk of death from cirrhosis of the liver and liver 
cancer (McMahon, 2009a). Over 240 million people have chronic (long – term) 
liver infections (Ott et al., 2012). More than 780.000 people die every year due to 
the acute or chronic consequences of hepatitis B (El-Serag, 2012). A vaccine 
against hepatitis B has been available since 1982. Hepatitis B vaccine is 95% 
effective in preventing infection and its chronic consequences, and was the first 
vaccine against a major human cancer.  
HBV GENOTYPES, SUBGENOTYPES AND GLOBAL 
DISTRIBUTION  
HBV is the prototypic member of a small group of enveloped DNA viruses 
termed hepadnaviridae (hepatitis DNA viruses) which are defined by a distinct 
liver tropism and a very narrow host range. The hepadnaviridae can be divided 
into two genera, the orthohepadnaviridae infecting mammals and 
avihepadnaviridae which exclusively infect birds. The HBV of human, 
woodchucks (WHV), ground squirrels (GSHV) and woolly monkeys (WMHV) 
are members of the orthohepadnaviridae (Dane et al., 1970); (Lanford et al., 
1998); (Marion et al., 1980); (Summers et al., 1978). The genus of 
avihepadnaviridae includes the hepatitis B virus of the Peking ducks (DHBV) and 
herons (HHBV) (Mason et al., 1980); (Sprengel et al., 1988). Similar to the 
family of retroviridae, the replication of hepadnaviridae occurs via a RNA – 
intermediate using the viral polymerase. To emphasize this relation, 
hepadnaviridae are often termed as pararetroviruses. 
Eight genotypes of HBV worldwide have been identified. When sequencing the 
entire viral genome, these genotypes differ from each other by more than 8%; 
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(Fung and Lok, 2004); (Kramvis and Kew, 2005); (Kramvis et al., 2005); 
(Miyakawa and Mizokami, 2003); (Schaefer, 2005). In addition, multiple 
subgenotypes have been and are continued to be identified, which differ from 
each other by 4 – 8%. The HBV genotypes identified to date are A, B, C, D, E, F, 
G, and H, of the HBV genome have been defined. Moreover, two new genotypes, 
I and J, have also been identified. Over 30 related subgenotypes belonging to 
HBV genotypes have been determined to date, but the mechanisms of different 
pathogenic characteristics of HBV genotypes are not known for certain. Many 
studies have reported that different genotypes and subgenotypes show different 
geographical distribution, and are related to disease progression, clinical 
progression, response to antiviral treatment, and prognosis. Subgenotypes for each 
genotype have been labeled by using the nomenclature 1, 2, 3, etc. Genotype A is 
divided into A1, found in sub – Saharan Africa, A2, in Northern Europe, and A3 
in Western Africa. The subgenotypes of HBV genotype B have been divided into 
two major groups: those found to be ‘‘pure’’ genotype B including B1 (formerly 
called Bj or B Japan) and B6, and those subgenotypes that have a recombination 
of part of the core region of HBV genotype C onto the genotype B core area 
including B2, B3, B4, and B5 (formerly called Ba or B Asia). Genotype B1 is 
found in Japan, B2 – 5 are found in East Asia, and B6, the newest identified B 
genotype, is found in indigenous populations living in the Arctic. Genotype C is 
divided into C1, C2, and C3 and is found in China, Korea, Southeast Asia, and in 
several South Pacific Island countries. Genotype D is widely spread across 
Eastern Europe, the Mediterranean regions, including North Africa, Russia, the 
Middle East, the Indian subcontinent, and across the Arctic. Genotype E is found 
in West Africa. HBV genotype G has been found only in small areas of the world, 
in the United States, Vietnam, and Southern Europe, and appears primarily to be 
present as a coinfection with another HBV genotype, most commonly genotype 
A. Genotypes F and H are the ‘‘New World’’ genotypes found in indigenous 
populations in Alaska and Central and South America. Genotype F is divided into 
4 subgenotypes: F1 – F4. Genotype H is very closely related to genotype F and 
was initially thought to be a clade of genotype F. In the 48 contiguous US states, 
genotypes A2, B, C, and D are more commonly found, with immigrants born in 
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endemic areas reflecting the HBV genotype of their country of origin (Chu et al., 
2003). Genotype I has recently been reported in Vietnam and Laos. The newest 
HBV genotype, genotype J, has been identified in the Ryukyu Islands in Japan. 
Geographic distribution of HBV genotypes may be related to route of exposure. 
For example, genotypes B and C are more common in high-endemic regions of 
perinatal or vertical exposure, which plays an important role in viral transmission. 
Other genotypes are primarily observed in regions of horizontal exposure 
(Schaefer, 2007). Therefore, genotyping provides an epidemiological clue in the 
investigation of acquisition, because this lies in the geographical distribution of 
HBV (Sunbul, 2014). Figure 1 shows genotype distribution across the world.  
 
 
 
 
 
 
   
            Figure 1 shows genotype distribution across the world. 
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MODE OF TRANSMISSION  
HBV is transmitted by percutaneous or mucosal exposure to infected blood or 
other body fluids. HBV transmission has been observed with numerous forms of 
human contact: perinatal/mother – to – child; household (nonsexual); sexual; 
needle – sharing; and occupational/health – care – related. The highest 
concentrations of infectious HBV are found in blood and serum. However, other 
serum – derived body fluids, such as semen and saliva, are also infectious (Bond 
et al., 1977). Persons with chronic HBV infection are the major reservoir for 
transmission. Because HBV can remain stable and infectious on environmental 
surfaces for at least 7 days, transmission may occur indirectly viacontaminated 
surfaces and other objects. Transmission from a chronically infected woman to 
her infant during delivery is efficient and is one of the most common routes of 
HBV infection worldwide. Perinatal transmission of HBV most often occurs 
during the birth process; in – utero transmission can occur but is rare and accounts 
for less than 2 percent of perinatal transmissions (Xu et al., 1985). Transmission 
of HBV can also occur in situations where there is frequent and prolonged close 
personal contact with an infected person (Davis et al., 1989).  Although the exact 
mode of transmission is unknown, transmission is hypothesized to occur from 
inapparent blood or body fluid exposures from parents, siblings, or playmates that 
inoculate HBV into cutaneous scratches, abrasions, or other lesions or onto 
mucosal surfaces (Francis et al., 1981). HBV is efficiently transmitted by sexual 
contact. Sexual contacts of chronically infected persons have been shown to have 
a higher seroprevalence of HBV infection than control populations, including 
household (nonsexual) contacts of infected persons (Alter and Margolis, 1990). 
Men who have sex with men (MSM) have long been known to have high rates of 
disease, and they have persistently higher HBV seroprevalence rates than the 
general population (MacKellar et al., 2001). Injection drug users are athigh risk 
for HBV infection because of behaviors suchas sharing of needles, syringes, and 
other drug paraphernalia. However, the risk among injection drug users can vary 
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depending on the prevalence of chronic HBV infection in the community, as well 
as drug – sharing and preparation practices. Outbreaks linked to other 
percutaneous exposures besides injection drug use, such as tattooing and 
acupuncture, have been reported (Limentani et al., 1979); (Kent et al., 1988). 
Health – care – related transmission has long been recognized as an important 
source of new HBV infections worldwide. Provider – to – patient, patient – to – 
provider, and patient – to – patient transmission have all been observed, although 
the frequencies with which these types of transmission occur are widely divergent. 
Patient – to – provider transmission was common before widespread hepatitis B 
vaccination of health care workers. A health care worker’s risk of infection has 
been shown to correlate with his orher level of blood and needle exposure (Hadler 
et al., 1985). Patient – to – patient HBV transmission is a major source of new 
HBV infections in the developing world. Patient – to – patient HBV transmission 
can result from percutaneous exposure to contaminated equipment used for 
injections or other procedures, or from blood or mucosal exposure to 
contaminated medication. In developing countries, exposures to contaminated 
therapeutic injection equipment are common in many settings because of lack of 
awareness of infection control practices, lack of resources for sterilization and the 
purchase of new disposable equipment, and economic incentives and cultural 
preferences favoring overuse of injections. In the developed world, outbreaks 
involving this type of transmission remain a persistent problem as well, and they 
usually stem from lapses ininfection control practice by health care workers. 
Implicated vehicles for transmission include multidose vials, finger – stick 
devices, acupuncture needles, and jet injection guns. Contaminated environmental 
surfaces in health care settings have also served as a reservoir for HBV 
transmission, particularly in dialysis units (Williams et al., 2004). Provider – to – 
patient HBV transmission is rarely reported. Most events have been associated 
with health care workers’ performing invasive procedures, and most occurred 
before the widespread use of hepatitis B vaccine and the implementation of 
universal precautions in standard infection control practice (Gunson et al., 2003). 
Transmission of HBV via transfusion of blood products has been largely 
eliminated in most parts of the world by screening blood donors and 
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implementing techniques that ensure viral inactivation of products made from 
blood, such as factor concentrates (Busch et al., 2003).  
 
GLOBAL PATTERNS OF TRANSMISSION  
The global epidemiology of HBV infection has traditionally been described 
according to three categories of endemicity – high, intermediate, and low – 
depending on the proportion of the population that is seropositive for HBsAg 
Figure 2. Countries with high endemicity are those where HBsAg seroprevalence 
is greater than or equal to 8 percent; countries with intermediate endemicity are 
those where seroprevalence is 2 – 7 percent; and those with low endemicity are 
those where seroprevalence is less than 2 percent. HBsAg seroprevalence has 
marked geographic variations, and the degree of HBV endemicity often correlates 
with the predominant mode of transmission. In highly endemic settings, perinatal 
and horizontal (exposure to chronically infected household members) routes are 
responsible for most disease transmission, and 70 – 90 percent of the adult 
population has serologic evidence of prior infection. Because hepatocellular 
carcinoma is a potential sequela of chronic HBV infection, highly endemic 
countries have markedly higher rates of liver cancer than countries with lower 
endemicity, and hepatocellular carcinoma is a major cause of mortality in these 
areas. Countries with intermediate endemicity have a mix of perinatal, horizontal, 
health – care – related, sexual, and other forms of transmission. In countries with 
low endemicity, most new infections occur among young adults and are acquired 
sexually or through injecting drug use. Highly endemic population subgroups may 
be present within low – endemicity countries, however, depending upon 
seroprevalence rates of immigrant groups and native/indigenous populations.  
Approximately 60 percent of the world’s population lives in areas where HBV 
infection is highly endemic, including China (total population, 1.3 billion), 
Indonesia (222 million), Nigeria (132 million), and much of the rest of Asia and 
Africa. Some notable examples of high pre – vaccine – era  burdens of disease 
include Taiwan, where 15 – 20 percent of the general population had chronic 
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HBV infection and 30 percent of those chronically infected were HBeAg – 
positive, and the Gambia, where the prevalence of chronic infection among 
children was 36 percent.  
Southern Europe, the Middle East, and South Asia have an intermediate level of 
HBV endemicity. HBsAg seroprevalence in India is approximately 5 percent, and 
the major modes of HBV transmission are perinatal, child – related/horizontal, 
and health – care – related, particularly unsafe injections. In Italy, Russia, and 
Turkey, the prevalence of chronic HBV infection ranges from 3 percent to 10 
percent, and unsafe injections have been implicated as a major route of HBV 
transmission.  
Most of Central and South America is considered a region of low HBV 
endemicity. However, the western Amazon basin, including Brazil and Peru, is a 
highly endemic area, with observed HBsAg seroprevalence rates greater than 10 
percent.  
Many developed nations, including the United States, fall into the low endemicity 
category. Just prior to the era of widespread hepatitis B vaccine use (1988–1994), 
0.42 percent of the US population was HBsAg – seropositive, and 4.9 percent had 
serologic markers of previous or current HBV infection. In the prevaccine era, 
some indigenous populations and immigrant groups within the United States had 
seroprevalence rates similar to those of highly endemic countries, and members of 
these populations comprised a disproportionate share of new HBV infections 
nationwide (Shepard et al., 2006).  
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Figure 2: Geographic distribution of the prevalence of chronic hepatits B virus infection 
(Shepard et al., 2006)  
 
MORPHOLOGY AND GENETIC ORGANIZATION  
MORPHOLOGY  
In electron microscopy, the infectious hepatitis B particle, called Dane particle, 
appears as a spherical double – shelled structure with a diameter of 42 – 47 nm as 
depicted in Figure3 (Dane et al., 1970). The  virion consists of a nucleocapsid 
which is surrounded by a lipid membrane. Beside host cell endoplasmic reticulum 
(ER) – derived lipids, the three viral surface proteins, the large – (L), the middle – 
(M) and the small – (S) protein are embedded in the viral outer membrane. The 
surface proteins differ in the length of their N – terminal domain and share a 
common hydrophobic part, the S – domain of 226 aminoacids aa. The M – protein 
contains the 55 aa N – terminal extension termed preS2 and the L – protein 
consists of an additional extension of 108 to 119 aa depending on the genotype, 
termed pre S1 (Patient et al., 2009). All three proteins are modified post 
translationally by glycosylation and the L – protein is additionally modified by 
myristoylation at its N – terminus (Heermann et al., 1984); (Persing et al., 1987). 
The  preS1 – domain of the L – protein displays a dual orientation and is directed 
to the lumen or exposed to the outside of the viral particle. Thereby the L – 
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protein is involved both in the envelopment of the nucleocapsids (inside) or 
receptor binding (outside) (Glebe and Urban, 2007). The icosahedral  
nucleocapsid is formed by HBcore – protein dimers and displays a T=3 (90 
HBcore – protein dimers) or T=4  symmetry (120 HBcore – protein dimers) 
depending on the number of HBcore – proteindimers (Bottcher et al., 1997). Both 
nucleocapsid types are present in infectious particles (Roseman et al., 2005). As a 
characteristic feature of hepadnaviridae, two types of subviral particles – spheres 
and filaments – can be detected in the serum of infected patients Figure3. In 
contrast to Dane particles, subviral particles only consist of a lipid envelope 
containing the viral surface proteins and therefore they are non – infectious 
(Heermann et al., 1984). They are secreted with an excess of 1000 – 100000 fold 
relative to the infectious particles and their function is still poorly defined, but it is 
suggested that they contributes to immune tolerance by neutralizing antibodies. 
  
 
Figure 3: HBV morphology. Infectious particles (Dane particles) are composed of a 
nucleocapsid (black) formed by HBcore – protein dimers which is surrounded by lipid 
layer which consists of the three viral surface proteins, the Large – (L), the Middle – (M) 
and the Small – (S) protein. In the nucleocapsid, the viral genome (red and blue line) is 
located which is covalently linked to the viral polymerase (green). Subviral particles-
spheres and filaments – are only composed of a lipid layer. 
 
VIRAL GENOME ORGANIZATION 
The HBV genome is a partially double – stranded circular DNA molecule called 
relaxed circular DNA (rcDNA). It represents one of the smallest genomes among 
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the DNA viruses and is formed by two linear strands of different length Figure 4 
(Summers et al., 1975). The coding minus strand comprises the complete coding 
capacity of approximately 3.2 kilo bases Kb, depending on the genotype, while 
the non – coding plus strand contains a variable 3 ́end and thus comprises only 50 
– 80% of the genome length (Hruska et al., 1977). The ends of the minus strand 
are not connected but the 5 ́end of the minus strand is covalently linked to the 
polymerase (Gerlich and Robinson, 1980). The 5 ́end of the plus strand consists of 
a short RNA – cap structure of about 17 – 19 nucleotides. The circularization of 
both strands is achieved by complementary regions at the 5 ́end of both strands 
containing the directed repeated sequences, DR1 and DR2 (Seeger et al., 1986) 
(Sattler and Robinson, 1979). A packaging signal, termed epsilon signal, is 
encoded by the minus strand. The HBV genome displays a highly compact 
structure and contains four partially overlapping open reading frames ORF which 
cover the entire genome and encode seven different HBV proteins. The three viral 
surface proteins (protein L, M and S) are encoded by the preS/S – ORF which 
consists of three 5 ́ in phase start codons for the initiation of the translation (Glebe 
and Urban, 2007). The HBcore – protein as well as soluble and secreted 17 kDa 
HB e antigen (HBeAg) is encoded by the preC/C – ORF. The polymerase with its 
typical domain structure is encoded by the P – ORF and the X – ORF encodes for 
the regulatory Hepatitis B virus proteinX (HBx).  
 
 
 
Figure 4: HBV genetic organization 
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REGULATORY ELEMENTS OF HEPATITIS B VIRUS 
TRANSCRIPTION  
HBV gene expression is tightly regulated by four different promoters and two 
enhancers (Enh I and Enh II) which contain binding sites for different 
transcription factors Figure5.  The preC/C promoter is a strong promoter; it allows 
the transcription of two RNAs: PreCore RNA and pgRNA of 3,5 kb each. The 
first transcript, longer for few nucleotides compared to the second, starts upstream 
of the protein PreCore ATG and brings to the sysnthesis of HBeAg protein. The 
second RNA starts downstream of PreCore ATG and it is called pgRNA. The 
pgRNA is the template for the translation of Core and Pol proteins. The preC/C 
promoter contains the region BCP (Basal Core Promoter) which brings non-
canonic TATA boxes, binding sites for ubiquitaries factors (SP1, COUP-TF1, 
PPAR, RXR and TR2) and hepatic nuclear factor (HNF3 and HNF4). It has been 
also shown that HNF4, COUP-TF1 and TR2 negatively regulates the synthesis of 
PreCore RNA, whilst PPAR, SP1 and RXR can activate PreCore and pgRNA 
expression (Moolla et al., 2002). The sequence CURS (Core Upstream Regulatory 
Sequence) is upstream of BCP and positively regulates the promoter (Yu and 
Mertz, 1996). Contrarily the NRE domain upstream of BCP inhibits the activity of 
PreCore promoter (Chen and Ou, 1995).  
The PreS1 promoter allows the initiation of transcription of 2,4 Kb mRNA for 
PreS1 protein. This promoter has a canonic TATA box interacting with TBP and 
TFIID transcriptional factor and with HNF1. PreS1 promoter activity can bee it 
her positively regulate by a positive regulation sequence binding NF1, SP1 and 
HNF3 (Raney et al., 1994) and negatively regulate by a CCAAT sequence in the 
PreS2 promoter in order to maintain the optimal stoichiometry of envelop proteins 
(Lu et al., 1995). 
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The PreS2 promoter initiate the transcription for two 2,1 kb RNAs: PreS2 RNA 
and sRNA. This promoter presents a CCAAT sequence binding NFY and CBF 
and two positive regulatory elements also able to repress the transcriptional 
activity of PreS1 promoter (Zhou and Yen, 1991).  
The X promoter starts the transcription of 0,9 kb RNA coding for X – protein 
(Zheng et al., 1994). It localizes 140 bp upstream of the transcription start site and 
it over laps the enhancer I in its 3' region. It  has LSR binding sites for hepatic 
factors (HNF3 and HNF4) and for ubiquitous transcription factor such as NF1, 
CREB/ATF, NRF1, RXR, COUP0TF, C/EBP, AP and c-Jun stimulating the 
mRNA expression (Guo et al., 1991); (Fukai et al., 1997).  
The enhancer I is composed of about 270 bp and it is located between the ORF S 
and X and it partially overlaps the X promoter. The enhancer I strongly stimulates 
the transcription of pgRNA, PreCore/CRNA and XRNA but it has amodest effect 
on the transcription of RNAs for enveloppe proteins. It is made of  distinct 
domains: regulatory domain at 5', a core central domain and a regulatory domainat 
3' (Fukai et al., 1997). The central domain presents binding sites for HNF3, 
RFX1, EFC, NF1, HNF1, HNF4 PPAR, COUP-TF and STAT3 (Bock et al., 
2000); (Waris and Siddiqui, 2002). The regulatory domains stimulates the 
enhancer I activity via its interaction with HNF1 and C/EBP. The enhancer I also 
has a role in the sequential activation of transcription of the viral RNA in the early 
maturing transactivating genes and allowing full functionality of the enhancer II 
rather responsible for the transcription of the late genes (Doitsh and Shaul, 2004). 
Also a ISRE/IRE motif has also been discovered at the domain of the enhancer I 
overlapping with ORF X. This pattern thus interacts with transcription factors of 
the IRF family and STAT allowing better transactivating activity of enhancer I 
(Belloni et al., 2012).  
The 105 bp enhancer II is localized upstream of BCP and it overlaps the sequence 
CURS in the PreCore/C promoter. It is composed of two regions (IIA and IIB) 
and stimulates the transcription of RNAs for enveloppe protein sand for X – 
protein. The region II A and II B don't have trans activator activity perse and they 
need to sinergistically cooperate (Yuh and Ting, 1990). The enhancer II presents 
many binding sites for ubiquitous and hepato – specific transcription factors such 
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SP1, HNF3, HNF4, PPAR, C/EBP, FTF, RXR and HFL but canal so be 
negatively regulated by NRE domain (Li and Ou, 2001); (Li et al., 1995); (Ishida 
et al., 2000). 
 
 
 
 
Figure 5: viral transcripts 
 
 
PROTEINS OF THE HEPATITIS B VIRUS  
The viral polymerase carries out several enzymatic functions that in other viruses 
are executed by indipendent enzymes, firstly the generation of minus starnd DNA 
from an RNA template (reverse transcriptase activity), secondly the degradation 
of the RNA template by its RNaseH activity and thirdly the generation of plus 
starnd DNA from a DNA template (DNA polymerase activity). The polymerase is 
attached covalently to viral minus strand DNA due to an unique mechanism of 
priming reverse transcription (Beck and Nassal, 1997); (Nassal et al., 1990). The 
viral polymerase is composed of around 850 aminoacids organized into four 
functional domains. The terminal protein (TP) domain is covalently attached 
through a tyrosine residue at position 63 to the 5' end of the negative strand of the 
viral DNA. The TP domain is followed by a spacer domain containing a hinge in 
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the protein backbone that allows the catalytic domain to be brought into the 
proximity with the DNA sequence attached to the TP domain.  Since the function 
of the spacer domain is structural rather than enzymatic, it can  accept a 
significant degree of sequence variability and numerous variants have been 
described in this region. The active site has two activities: a revesre transcriptase 
function (RT) and a DNA – dependent DNA polymerase activity. The RT 
functions is responsible of the reverse transcription of the pgRNA from the minus 
strand. The active site contains a tyrosine – methionine – aspartate – aspartate 
(YMDD) motif that is identical to that identified in retrovirus reverse 
transcriptase. The DNA – dependent DNA polymerase activity allows the 
synthesis of the positive strand using the minus strand as template and thus the 
formation of the relaxed circular DNA. Finally the C – terminal domain of the 
protein presents an RNaseH activity that allows degradation of the RNA template 
once reverse transcription has taken place (Radziwill et al., 1990).   
The viral capsid is formed by the HBc antigen, a small protein of 183-185 
aminoacids. Two protein domains with specific functions can be distinguished: 
the N – terminal domain (NTD) and the C – terminal domain (CTD) (Chain and 
Myers, 2005). The NTD is involved in the formation of core dimers and in their 
self – assembly into capsids. The core protein homodimers assembles in 
ichosaedrical capsids with a T=3 to T=4 symmetry via oligomerization of 180 or 
240 monomers respectively (Crowther et al., 1994). Each monomer  contains a 
conserved cysteine at position 61 that can form an intradimer disulfide. In vitro 
HBV assembly is nucleated by a trimer of dimers and proceeds by the addition of 
individual dimeric subunits. Empty capsids assemble at a rate that is a function of 
protein concentration and ionic strength (Zlotnick et al., 1999). The CTD domain 
is involved in pgRNA incapsidation and DNA  replication (Gallina et al., 1989). 
A basic sequence mostly composed of arginines and serines undergoes 
phosphorylation and lead to the interaction between capsid and pgRNA or viral 
DNA (Nassal et al., 1990). Particularly three serines in position 155, 162 and 170 
are important for pgRNA encapsidation and viral replication (Liao and Ou, 1995). 
The phosphorylation state of the core protein is associated with nucleocapsid 
mauration: immature nucleocapsids, highly phosphorilated, are gradually 
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dephosphorilated during rcDNA synthesis (Basagoudanavar et al., 2007). Only 
mature capsids can interact with envelop proteins at the ERGIC (post ER, pre 
Golgi compartment) (Dryden et al., 2006). Newly synthetized nucleocapsids 
interplay with the NPC as the CTD domain act as a NLS sequence (Kann et al., 
2007).   
The protein PreCore is synthesized as a precursor polypeptide of 25 kDa. The N – 
terminal part, coded by precore, is very hydrophobic and plays the role of signal 
peptide to address the protein in the ER, where it undergoes different stages of 
maturation. The first clivage of 19 aminoacids in the PreCore domain gives the 
P22 only 10 aminoacids different from the core protein. Then, at the Golgi, the 
basic C – terminal tail of the precursor P22 can be cleaved to form the 17 kDa 
HBe antigen. The intracellular form of PreCore protein is able to assemble to form 
empty capsids (Kimura et al., 2005). This pseudo – capsids can be envelopped 
and secreted (Watts et al., 2011).   
The HBs antigen, composed of 226 aminoacids, is the principle envelope protein 
of the virus. The HBs protein can self – assembly into empty viral envelopes even 
in the absence of other viral proteins or nucleic acid. Together with two longer 
proteins, the M (middle) and the L (large) proteins, it is inserted in the lipid  
bilayer surroundig the viral capsid. They are encoded in one open reading frame 
and share the C – terminal S – domain which provides four trans – membrane 
helices 4 and is probably involved in fusion. In the M and L proteins, the amino 
acids sequence of HBs is extended at the N – terminal by 55 (PreS2 domain) and 
100 – 120 (PreS1  domain) additional aminoacids (Glebe and Urban, 2007).  
These extended sequence contain glycosylation sites that are processed in the 
Golgi apparatus. This myristoylation of the preS1 site is essential to render the 
viral particle infectious, in particular the myristoylation of a short sequence of the 
2048 aa in the preS1 has been identified as responsable for the binding to the virus 
receptor, the Na – taurocholate transporter (NTCP) (Meier et al., 2013); (Ni et al., 
2014).   
The hepatitis B virus X – protein (HBx) with a molecular mass of 17kDa is the 
smallest protein expressed by HBV. HBx is an unstructured protein with a folded 
C – terminal and a disordered N – terminal region. HBx exhibits a dual 
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localization. In transfected hepatoma cells and in liver biopsies of HBV – infected 
patients, HBx could be detected in the nucleus and in the cytoplasm (Haruna et 
al., 1991); (Su et al., 1998); (Nomura et al., 1999). Moreover, a portion of the 
cytoplasm fraction is localized at the outer membrane of the mitochondria 
(Rahmani et al., 2000); (Huh and Siddiqui, 2002); (Kim et al., 2007); (Clippinger 
and Bouchard, 2008). The dual localization displays the multiple functions of 
HBx in different cellular processes in the cytoplasm and nucleus including cell 
cycle regulation, apoptosis, activation of signaling pathways, autophagy, 
proteasomal protein degradation, DNA repair and transcription (Benhenda et al., 
2009). Since HBx cannot bind directly to DNA, it is suggested that the pleiotropic 
transcriptional activity is caused by two mechanisms, first the interaction with 
transcriptional regulators in the nucleus, such as TFIIB, TFIIH, TBP, RBP5, 
CBP/p300 (Lee et al., 2001); (Cougot et al., 2007) and  secondly by activating 
different signal cascades in the cytoplasm including MAPK, SAP/JNK, p38, 
JAK/STAT pathway. Activation of the signaling cascades in turn results in the 
activation of different transcription factors including NF-kB, hypoxia – inducible  
factor 1a (HIF-1) or activator protein 1 (AP-1) (Benn and Schneider, 1994); (Lee 
and Yun, 1998); (Kim et al., 2001). HBx can modulate many different pathways 
by direct protein – protein interaction with HBXIP, p53, DDB1, HDAC1 and 
CREM1 (Fujii et al., 2006); (Feitelson et al., 1993); (Lee et al., 1995); (Forgues et 
al., 2001). Several studies showed the importance of HBx in the viral replication 
by demonstrating that HBx expression in tissue cultures or animal models could 
restore the low replication from HBx – deficient HBV plasmids (Zhang et al., 
2004);  (Keasler et al., 2009);  (Tang et al., 2005). Recently, two studies have 
proved that HBx is indispensable for the complete authentic HBV infection in 
vitro and in vivo. In authentic tissue culture systems (HepaRG cells and PHHs) 
and in human hepatocytes chimeric mice, the replication of HBV deficient for 
HBx was strongly impaired and could be restored by WT HBx expression (Tsuge 
et al., 2010). It is suggested that HBx either regulates the HBV DNA 
transcription, DNA replication, pgRNA endcapsidation, phosphorylation of 
HBcore – protein or polymerase activity (Zhang et al., 2004); (Tang et al., 2005); 
(Melegari et al., 2005); (Cha et al., 2009). Recently, it was shown that HBx is 
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essential for the transcriptional regulation of the cccDNA: HBx is recruited onto 
the cccDNA, binds to CBP/p300 and prolongs the activity of CREB and thereby 
regulates the acetylation status of cccDNA bound histones 3 and 4 resulting in the 
stimulation of cccDNA transcriptional activity (Cougot et al., 2007); (Belloni et 
al., 2012); (Lucifora et al., 2011). In the absence of HBx, cccDNA – bound 
histones are hypo – acetylated, and the cccDNA transcribes significantly less 
pgRNA (Belloni et al., 2009). HBx also binds and blocks the inhibitory activity 
on HBV transcription exerted by the PRMT1 methyltransferase (Benhenda et al., 
2013), the Tudor – domain protein Spindlin-1 (Ducroux et al., 2014) and the 
SETDB1 histone methyltransferase (Riviere et al., 2015). Additional mechanisms 
by which HBx can potentiate HBV replication include: a) the downregulation of 
DNMT3A expression through the induction of miR-101 (Wei et al., 2013); b) a 
direct transcriptional activation of genes and miRNAs that potentiate endocytosis 
(RAB family) and autophagy (Guerrieri, 2015) both required for viral replication 
(Huang et al., 2012); (Macovei et al., 2013); (Sir et al., 2010); c) binding to the 
UV-DDB1 protein (Hodgson et al., 2012) and inactivation of the Smc5/Smc6 – 
mediated restriction of cccDNA transcription (Strubin et al. presented at the HBV 
Molecular Biology Meeting 2015); d) the elevation of cytosolic calcium levels 
(Yang and Bouchard, 2012) and e) the direct transcriptional repression of 
miRNAs (miR-138, miR-224, miR-596) that inhibit HBV replication by directly 
targeting the HBV pgRNA (Guerrieri, 2015). 
The genome – wide analysis of HBx chromatin recruitment in HBV replicating 
cells (Guerrieri, 2015) revealed a specific binding of HBx to a large number target 
sequences, including protein – coding genes and non – coding RNAs (16 lncRNA 
promoters and 32 lncRNA intragenic regions, 44 snoRNA, 3 snRNA and 75 
miRNA promoter regions) (Guerrieri, 2015). Pathway analysis showed an 
enrichment in genes/non – coding RNAs involved in cell metabolism, chromatin 
dynamics and cancer as well as genes/non – coding RNAs known to modulate 
HBV replication (RAS, calcium transport, endocytosis, MAPK/WNT pathways, 
SRC and the EGF/ HGF family) (Guerrieri, 2015).  
Mechanistically, the activity of HBx on transcription of both cellular genes and 
the viral genome rely on the modulation of epigenetic modifications and the 
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interaction with multiple transcription factors (ATF/CREB, ATF3, c/EBP, NF-
IL6, ETS, EGR, SMAD4, OCT1, RXR receptor and p53), chromatin modifying 
enzymes (CBP, p300 and PCAF) and component of the basal transcriptional 
machinery (RPB5, TFIIB, TBP and TFIIH).  
  
  
VIRAL REPLICATION CYCLE  
Replication of the hepadnaviral genome can broadly be divided into three phases: 
infectious virions contain in their inner icosahedral core the genome as a partially 
double – stranded, circular but not covalently closed DNA of about 3.2 kb in 
length (relaxed circular, or rcDNA); upon infection, the rcDNA is converted, 
inside the host cell nucleus, into a plasmid – like covalently closed circular DNA 
(cccDNA); from the cccDNA, several genomic and subgenomic RNAs are 
transcribed by cellular RNA polymerase II; of these, the pregenomic RNA 
(pgRNA) is selectively packaged into progeny capsids and is reverse transcribed 
by the co – packaged P protein into new rcDNA genomes. Figure 6 pictures the 
HBV replication cycle.   
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Figure 6: HBV replycation cycle (Chan et al., 2011) 
 
 
ENTRY AND RELASE INTO THE CYTOPLASM 
Although there has been much research into the pathogenesis and treatment of 
hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, we still do not 
completely understand how these pathogens enter hepatocytes. This is because in 
vitro infection studies have only been performed in primary human hepatocytes.  
Development of a polarizable, HBV – susceptible human hepatoma cell line and 
studies of primary hepatocytes from Tupaia belangeri have provided important 
insights into the viral and cellular factors involved in virus binding and infection 
(Urban, 2008). According to a general concept of viral infection, the first step is 
an energy – independent attachment of the viral particle to a structure at the host 
cell surface. After the primary attachment, which is characterized by low affinity 
and reversibility, the virus particle is transferred to a more specific receptor. HBV 
infection is thought to follow a multistep process. There are reports about the 
relevance of the initial attachment to the carbohydrate side chains of hepatocyte – 
associated heparan sulphate proteoglycans as attachment receptors for HBV 
25 
 
infection (Schulze et al., 2007). This interaction is suggested to initiate the 
multistep entry process of HBV and is followed by a high-affinity step mediating 
HBV uptake. Using PHHs, 2 groups showed that N – terminal myristoylation of 
the HBV L protein is essential for virus infectivity (Gripon et al., 1995); (Bruss et 
al., 1996). Because myristoylation also occurs in the L proteins of woodchuck 
HBV and duck HBV (Macrae et al., 1991), this modification has a general role in 
hepadnaviral infection, presumably by increasing receptor binding (De Falco et 
al., 2001). In a systematic approach, Le Seyec et al. mapped functionally 
important sites in the preS1 and preS2 domains of the L protein. Consecutive 
deletions of 5 aa within the N – terminal 77 aa of the L protein blocked infectivity 
(Le Seyec et al., 1998). A second determinant of infectivity is located in 
theantigenic loop AGL of the S domain. Mutation analysis revealed that Gly-119, 
Pro-120, Cys-121, Arg-122, and Cys-124 are required for infectivity (Jaoude and 
Sureau, 2005). Besides these envelope protein determinants, the lipid composition 
of the viral membrane is crucial for infectivity. Although depletion of cholesterol 
from cellular membranes with methyl – b – cyclodextrin has little effect on 
infection, depletion from the virus membrane strongly reduces infectivity in a 
reversible manner. This indicates a raft – independent localization of the virus 
receptor and suggests that a defined membrane association of HBV envelope 
proteins is required for productive entry (Bremer et al., 2009). Evidence that the 
preS1 domain of the L protein is involved in recognition of a hepatocyte – specific 
receptor came from the observation that a myristoylated peptide, thepreS1 
infectivity determinant, comprising 2–78 aa (Le Seyec et al., 1999), inhibited 
HBV infection of HepaRG cells and PHH. Consistent with this observation, L 
protein – containing SVP (small viral particle) bound specifically to PTH. 
Mutational sequence analyses revealed the requirement for 9-NPLGF aa (F/L) P-
15 motif, located at slightly variable positions within the N – terminus of the 
preS1 domain (Glebe et al., 2003). Studies of HepaRG cells, PHH, and PTH 
found that heparin and highly sulfated polysaccharides interfere with HBV 
infection (Leistner et al., 2008). HBV infection is sensitive to heparinases or 
sodium chlorate, indicating that the viruses use HSPGs as attachment sites 
(Sureau and Salisse, 2013). For many years groups worldwide had struggled to 
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identify, and confirm the functionality of host molecules needed for HBV and 
HDV entry. Many candidates were identified but none were shown to be 
sufficient for virus entry and initiation of replication (Urban, 2008). This situation 
was changed dramatically in late 2012 by a report from Yan et al. They used a 
synthetic peptide corresponding to the myristoylated N – terminus of the HBV 
preS1 protein to affinity select a candidate virus receptor from hepatocyte 
cultures. They identified the protein as the sodium taurocholate cotransporting 
polypeptide, NTCP, also known as SLC1-A1 (Yan et al., 2012). NTCP transports 
bile acids from the blood into the liver. Their subsequent findings included 
evidence that the cDNA clone of human NTCP, when transfected into human 
hepatocellular carcinoma cell lines, specifically HepG2 and Huh7, conferred 
susceptibility to both HBV and HDV. Susceptibility could be inhibited by the 
synthetic preS1 peptide. In a different approach, Ni et al. took advantage of the 
observation that DMSO induces HepaRG cell differentiation and expression of the 
HBV receptor (Ni et al., 2014). Comparing the expression profiles of 
undifferentiated and differentiated HepaRG cells and using stringent selection 
criteria, they found hNTCP to be the most strongly induced membrane protein. 
They confirmed the findings of Yan et al, showing that hNTCP-expressing HepG2 
and HuH7 cells support  high – level infection by HBV and HDV when cultured 
in the presence of DMSO. Once bound the NTCP the virus enter the cell. HBV 
does not possess a classic fusion peptide sequence (Berting et al., 2000); (Marsh 
and Helenius, 2006). In a recent report, a fusogenic function was ascribed to the 
PreS1 domain of HBV (Nunez et al., 2009). Based on sequence analysis, it was 
suggested by Rodriguez-Crespo et al. that the  N – terminus of the S – domain (1–
23 aa) might act as a fusogenic sequence (Rodriguez-Crespo et al., 1999), but so 
far there is no direct experimental evidence for fusion to host cell membranes 
during HBV entry. In the case of genotype D, the PreS2 domain of HBV harbors 
between 41–52 aa a membrane – permeable peptide designated TLM 
(translocation motif). The presence of this TLM is conserved in all hepadnaviridae 
(Oess and Hildt, 2000). The TLM belongs to the family of membrane – permeable 
peptides. Fusion of the TLM to other peptides or proteins enables their energy and 
receptor – independent translocation across cellular membranes into the 
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cytoplasm. Fusion of the TLM to HBcAg revealed that fully assembled 
nucleocapsids that are decorated on their surface with TLM – peptides are able to 
translocate across cellular membranes and deliver the packaged nucleic acid to the 
nucleus (Brandenburg et al., 2005) experiments revealed that in the endosomal 
compartment a proteolytic processing of the internalized viral particle occurs, 
resulting in an unmasking of the TLM peptide. It was concluded that, due to the 
endosomal proteolytic processing, unmasked TLM enabled the translocation 
across the endosomal membrane into the cytoplasm, where the proteolytically 
processed envelope dissociates from the nucleocapsid (Stoeckl et al., 2006). 
Recently it has been described in a immortalized PHH line that HBV can use a 
clathrine – dependend endocytosis mechanism to enter the hepatocyte.   
 
 
 
rcDNA TO cccDNA CONVERSION 
At the end of the viral entry process, the viral genome is delivered into the 
nucleus. The viral genome exists at this stage as rcDNA. rcDNA consists of a 
complete (-)-DNA strand covalently linked to the viral polymerase P at its 5’ end, 
and an incomplete (+)-DNA strand with an RNA oligonucleotide at its 5’ end, 
which serves as primer for the (+)-strand synthesis. To establish a viral infection, 
the viral genome has to be present in a stable form within the infected cell. In the 
case of HBV, the viral rcDNA is converted into a nuclear, episomal cccDNA, 
which represents the central intracellular intermediate in viral replication (Jun-Bin 
et al., 2003); (Sun and Nassal, 2006). In addition to incoming virion DNA, 
cccDNA can also be produced from newly synthetized cytoplasmic core DNA 
through an intracellular amplification pathway during the early phase of infection 
(Wu et al., 1990). This two pathways culminate in the formation of a regulate 
steady – state population of 5 to 50 cccDNA molecules per infected hepatocyte. 
The longevity of cccDNA is still in debate (Newbold et al., 1995). At least four 
steps are involved in the conversion of gnomic rcDNA to cccDNA: repair of the 
single – stranded gap region; removal of the 5' – terminal structures, including the  
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capped oligoribonucleotide on the plus strand and HBV Pol protein on the minus 
strand; removal of the short terminal redundancy of the minus strand; and 
covalently ligation of both strand, thus forming cccDNA. Considering the 
structural feature of core – associated rcDNA, removal of viral DNA polymerase 
from the 5r terminus of minus strand DNA ought to be an essential step in 
cccDNA biosynthesis. Indeed, it has been demonstrated that the hypothetic 
deproteinized rcDNA (DP-rcDNA) species existed in the virally infected 
hepatocytes in vivo and transfected hepatoma cells in cultures. Detailed 
characterization of DP-rcDNA led to propose a working model of cccDNA 
biosynthesis pathway (Guo et al., 2010). Further synthesis of plus strand DNA 
toward completion triggers the removal of genome – bound polymerase protein 
and nucleocapsid structure change, which leads to the exposure of a nuclear 
localization signal (NLS) at the carboxyl – terminus of capsid protein. The NLS in 
turn mediates the importation of the DP-rcDNA containing capsid into the nucleus 
(Kann et al., 2007). It was demonstrated that unlike rcDNA, which formed 
cccDNA through faithful repair of the nicks in both plus and minus strand DNA, 
the double – stranded linear DNA (dslDNA) was converted into either cccDNA 
with deletions or insertions around the junction site, or oligomeric forms in  which 
monomers were joined near the ends in random orientation, apparently via intra- 
or inter- molecular recombination (Yang and Summers, 1995). Similar with 
deproteinization of rcDNA, Guo et al. observed that deproteinized dslDNA (DP-
dslDNA) appeared 24h earlier in the cytoplasm than cccDNA in the nucleus, 
suggesting that deproteinization of dslDNA also primarily takes place in the 
cytoplasm. These observations further supported the hypothesis that the removal 
of covalently attached viral polymerase from hepadnaviral  mature genome DNA 
takes place in the cytoplasm and the resulting DP -rc and -dslDNA are 
subsequently imported into the nuclei, where they are converted into cccDNA. As 
illustrated in Figure 7, based on their unique structural features, DP -rcDNA and -
dslDNA have been speculated to be converted into cccDNA by distinct cellular 
DNA repair machinery. While it is generally believed that multiple DNA repair 
components/pathways might participate in repair of the two gaps in rcDNA during 
cccDNA formation (Sohn et al., 2009), it is also postulated that rcDNA may at 
29 
 
first be converted into a double – stranded linear DNA containing terminal repeats 
(TR-dslDNA) through extension of both plus and minus strand DNA over the 
cohesive – end region by viral and/or host DNA polymerases, and cccDNA is 
subsequently formed via intra - molecular homologous recombination of TR-dsl 
DNA. Although the TR-dsl DNA is undetectable in virally infected hepatocytes 
by conventional hybridization methods, previous sequence analysis of cccDNA 
recombinant joints in the livers of DHBV – infected ducks and WHV – infected 
woodchucks provided evidence supporting that cccDNA could be formed from 
two types of linear DNA, the dslDNA derived from in situ priming and the 
putative TR-dsl DNA, through nonhomologous recombination (Yang et al., 
1995). Guo and coworkers vigorously confirmed that NHEJ pathway is indeed 
required for cccDNA formation from the dslDNA, but not rcDNA precursor.  
 
 
 
 
 
Figure 7:  Schematic representation of cccDNA biosymthesis pathways from rc and 
dslDNA   
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The HBV genome gain access to the nucleus via the importin pathway using 
nuclear transport receptors Imp-β/Imp-α. The cccDNA is organized into 
minichromosomes in the nucleus of the infected cell by histone and non-histone 
proteins Figure 8. Histone proteins H3 and H2B are the most prominent  species 
but lower levels of histone proteins H4, H2A and H1 are also detectable. In 
contrast to cellular chromatin the nucleosomal spacing of the HBV 
minichromosome has been shown to be unusually reduced by approximately 10%.  
In vivo and in vitro experiments indicated that HBV core protein is a component 
of the HBV minichromosome, binds preferentially to HBV double – stranded 
DNA, and its binding results in a reduction of the nucleosomal spacing of the 
HBV nucleoprotein complexes by 10% (Bock et al., 2001). 
 
 
 
 
Figure 8: electron microscopy of in vitro reconstituted HBV nucleoprotein complexis 
 
cccDNA TRANSCRIPTION  
All known hepadnaviral RNAs, i.e. the subgenomic RNAs as well as the greater –
than – genome length pgRNA and preCORE RNA, are transcribed by cellular 
RNA polymerase II (the enzyme responsible for cellular mRNA synthesis) using 
cccDNA as the template. All contain 5 ́ cap structures, all are 3 ́terminally poly – 
adenylated at a common site, and all serve as mRNAs for viral gene products. 
Spliced transcripts do exist, and even can be packaged into progeny virions, yet 
their functional role is still obscure (Sommer et al., 2000). The transcript relevant 
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for virus replication is the pregenomic RNA (pgRNA), encompassing the entire 
genome length plus a terminal reduncancy of, in HBV, about 120 nt that contains 
a second copy each of the direct repeat 1 (DR1) and the ε signal, plus the poly – A 
tail Figure 9. The pgRNA starts immediately after the preCORE initiator codon. 
Its first essential role is that as mRNA for the core protein and the reverse 
transcriptase; unlike retroviral Gag-Pol proteins, P is expressed as a separate 
polypeptide by an unconventional mechanism (Sen et al., 2004). Secondly, 
pgRNA is the template for generation of new DNA genomes by reverse 
transcription. The 5 ́ terminally extended preCORE RNA contains the initiator 
codon of the preC region and gives rise to the 25 kDa preCORE precursor protein 
of secreted 17 kDa HBeAg. It is unsuited as a pregenome, and is excluded from 
participating in replication on the level of encapsidation (Nassal et al., 1990). 
Efficient transcription of HBV genes requires a number of ubiquitous 
transcription factors. NF-1 and Sp1 probably contribute to differential regulation 
of HBV gene expression. NF-1 has three different binding sites within HBV 
genome: the site 190 bp upstream S – ptomoter is essential for its optimal activity 
(Shaul et al., 1986); the binding site between the Enh I and core promoter is 
responsible for the suppression of enhancer function (Spandau and Lee, 1992); the 
site within the Enh I has a central role in HBV gene transcription (Ori et al., 
1994). Sp1 binding site in the Enh II positively regulates transcription of all HBV 
genes; the upstream Sp1 binding site in contrast was described to negatively 
regulate transcription of S and X genes (Li and Ou, 2001). TBP binds to the 
putative TATA-like sequence and the initiator sequence in the preS2/S promoter 
region that is necessary for the promoter activity (Bogomolski-Yahalom et al., 
1997). Qin et al showed that Enh II/Core, preS1 and Enh I/ X promoter are targets 
for Prox1 – mediated repression (Qin et al., 2009). Lin et al showed the 
requirement of CREB for expression of all HB antigens, HBV pgRNA and virus 
replication. The NF-KB indirectly inhibits synthesis of all HBV RNAs (Lin et al., 
2009). Although ubiquitous transcription factors do not confer hepatocyte  
tropism to HBV, they are essential for basal activity of HBV promoters and 
enhancers, for differential expression of HBV genes as well as for adaptation of 
HBV gene transcription to change the intra- and extra- cellular milieu. A number 
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of liver – enriched transcription factors and nuclear receptors have been shown to 
bind HBV promoter/enhancers elements and to be critical in activating and 
regulating HBV transcription. Chen et al found that HNF3α, HNF3β, HNF3γ, 
bind to Enh I and increase its activity 15 fold. Li et al moreover showed that 
HNF3α and HNF3β bind to Enh II and activate it in a dose dependent manner (Li 
et al., 1995). As HNF3 was shown to be able to bind its sites in compacted 
chromatin to open local nucleosomal domain (Cirillo et al., 2002), it is reasonable 
to speculate that the key role of HNF3 may be to bind the cccDNA and thus to 
provide acces for other transcriptional regulators. C/EBP can bind and activate the 
Enh II in a dose – dependent manner (Lopez-Cabrera et al., 1991); another 
binding site of C/EBP was found in the S promoter and shown to be necessary for 
full S promoter activity (Bock et al., 1999). Hepatocyte nuclear factor1 is 
expressed in two forms: HNF1α and HNF1β. HNF1α increases transcription from 
preS1 promoter (Raney et al., 1991), interacting with Oct1 (Zhou and Yen, 1991). 
Raney et al. overexpressed HNF4a in HepG2.1 cells and found that it increased 
the level of transcription from preS1, preS2/S and core promoters; they identified 
two binding sites in the core promoter and in the Enh I/X promoter region. HNF4 
inhibited transcription from the preC promoter and activated transcription from 
the pregenomic promoter. Overexpression of HNF4 increased synthesis of HBV  
pregenomic RNA (Yu and Mertz, 2003). HNF4a appears to be a major regulator 
of pgRNA transcription and thus HBV core and polymerase protein production 
and HBV replication. Raney et al. found that PPARa-RXRa heterodimers increase 
transcription from the pres1, the core and the Enh I/X promoters. Overexpression 
of PPAR-RXR resulted in stimulation of pregenomic RNA transcription (Yu and 
Mertz, 1997). FXRa-RXRa heterodimers can bind to HBV Enh II and core 
promoter (Ramiere et al., 2008). TR4 represses the HBV core promoter via 
inhibition oh HNFa – mediated transactivation by protein – protein  interaction 
(Lin et al., 2003).  
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REVERSE TRANSCRIPTION: FROM THE pgRNA TO THE rcDNA  
The next crucial step in hepadnaviral replication is the specific packaging of 
pgRNA, plus the reverse transcriptase, into newly forming capsids. Key actors are 
cis-elements on the pgRNA, most notably the encapsidation signal ε and P protein 
which binds to ε. This interaction, in a still poorly understood fashion, mediates 
recruitment of core protein dimers and thus leads to packaging of the pgRNA-P 
complex. Remarkably, the preCORE RNA is not packaged although it contains all 
of the sequence comprising the pgRNA. Likely, active translation from the 
upstream precore ATG through the ε sequence prevents the P-ε interaction 
(Nassal et al., 1990). This implies, in turn, that P binding to ε on the pgRNA 
interferes with translation of the core ORF, and evidence supporting this view has 
been forwarded for DHBV (Cao and Tavis, 2006). Once pgRNA and P protein are 
being encapsidated a second key function of the P-ε interaction is brought to bear, 
namely the initiation of reverse transcription. At this stage the first DNA 
nucleotide (nt) is covalently linked to P protein, extended into a complete (-) 
strand DNA, and (+) strand DNA synthesis ensues, giving rise to a new molecule 
of rcDNA; the various immature DNA forms in status nascendi are termed 
replicative intermediates. The absolute requirements for replication are a template 
nucleic acid, plus an enzyme that is able to read the template information and use 
it for synthesis of a complementary nucleic acid. Clearly, these basic components 
are the pgRNA (and later the (-)-strand DNA) and P protein. However, generation 
of a functional genome also depends critically on precise start and end points, 
provided by cis – elements on the template Figure 9; a further specialty of P 
protein is its strict dependence, for activity, on cellular factors, namely heat shock 
proteins (Hsp ́s) or chaperones. The best understood cis – element on the 
hepdnaviral pgRNA is ε, a stem – loop structure initially defined as the sequence 
from the 5 ́ end of HBV pgRNA that P – dependently mediated encapsidation of 
pgRNA, and also of heterologous transcripts to which it was fused (Junker-
Niepmann et al., 1990); later, the P-ε interaction was found to constitute the first 
step in initiation of reverse transcription (Wang and Seeger, 1993); (Tavis et al., 
1994); hence ε also acts as the replication origin. HBV ε, however, does not act as 
a completely autonomous encapsidation element. The 3 ́ copy of ε cannot 
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substitute for 5 ́ ε in the context of otherwise authentic pgRNA (Rieger and 
Nassal, 1996). Furthermore, 5 ́ ε mediates encapsidation of heterologous RNAs 
only up to a limited distance from the 5 ́ end (about 65 nt), and seems to require 
the 5 ́ cap structure (Jeong et al., 2000). Hence the 5 ́ cap and factors bound to it 
appear to have a role in the process, possibly in concert with the 3 ́ poly – A tail 
and its associated cellular proteins. in all P proteins two conserved domains have 
been found, namely the polymerase/reverse transcriptase (RT) domain, and the C 
– terminal RNase H [RH] domain. Both are necessary as structural components 
for pgRNA encapsidation (Bartenschlager et al., 1990). An absolutely 
hepadnavirus – specific feature is, however, the Terminal Protein (TP) domain at 
the N terminus, separated from the RT domain by a highly variable, and 
dispensable, spacer (Radziwill et al., 1990). TP was first identified as the (-)-DNA 
linked protein (Bartenschlager and Schaller, 1988) and later was shown to provide 
a specific Y residue to which the first nt of the (-)-DNA becomes covalently 
linked. The P protein activity dependes on cellular chaperones. It was initially 
proposed that Hsp70 and Hsp90 and their respective co – chaperones, are essential 
for P activation (Hu et al., 1997). It has been shown that the chaperones convert 
the inactive P protein transientely into an active form, P*, which is able to bind ε 
RNA (Tavis et al., 1998). P activation appears to follow a double – hit, then run 
mechanism (Stahl et al., 2007): the first hit is the transient, energy consuming 
conformational change in P that exposes the RNA binding site, creating P*; this 
remains without consequences unless ε RNA is bound. However, after ε RNA 
binding and/or priming, P may gain autonomous, chaperone – indipendent DNA 
synthesis activity (P'), perfectly suited to continue DNA synthesis after e has been 
replaced as template by the 3' proximal DR1*. A first – though not the only – 
requirement for a productive P-ε interaction is specific binding. In many RNA – 
protein interactions, structural diversity and hence specificity is achieved by 
deviations from a fully base – paired doublehelical structure, e.g. by interspersed 
single – stranded bulges and loops. Indeed, the ε bulge structure (but not its actual 
sequence, unless it affects structure) is absolutely necessary for P binding. 
Mutants in the upper stem which favor stable non – bulged structures do not bind 
to P (Beck and Nassal, 1997). Similarly critical is the sequence and structure at 
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the junction between the lower stem and the bulge. The existence of Dε RNA 
variants which bind P but have a much reduced or no template activity indicated 
that a productive P-ε interaction requires more than binding (Pollack and Ganem, 
1994). It is likely that the RNA, after an initial binding step, must experience an 
induced – fit alteration into a new structure, and that only this is usable as a 
template. Also P protein undergoes structural alterations in this process. 
Proteolysis of in vitro translated DHBV P protein yielded a distinct proteolytic 
fragment only in the presence of priming – competent but not priming – inactive 
RNA variants (Tavis et al., 1998). Hence RNA and P protein mutually alter each 
others conformation, likely to properly arrange the ε template region and the 
priming Y residue of TP in the active site of the RT domain. Notably, of the 
various P binding RNAs only those that are priming – active also support pgRNA 
encapsidation. Hence the abilities to initiate reverse transcription, to package 
pgRNA, and to adopt a distinct RNA-P protein complex conformation appear 
strictly coupled. In effect, this represents a quality control mechanism ensuring 
that only RNAs suitable as templates for reverse transcription are packaged.  
 
 
 
 
 
 
Figure 9: pgRNA organization. The pgRNA is shown with some major cis – elements, 
i.e. ε (hairpin structure), DR1, DR2, and DR1*  
 
 
The initial model of hepadnaviral (-)-DNA formation assumed that synthesis 
would start inside the 3 ́ copy of DR1 (DR1*), for HBV at the motif 5 ́ UUCA. 
The complementary sequence 3 ́ AAGT at the 5 ́ end of (-)-DNA is instead copied 
from the UUCA motif in the ε bulge. Hence the oligonucleotide bound to TP must 
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specifically be translocated to the 3 ́ DR1*, nearly 3 kb apart from 5 ́ ε. One model 
is that DR1* and 5 ́ ε are brought into close proximity. A general mechanism 
would be closed-loop formation of the pgRNA via cellular proteins such as 
elongation initiation factor 4G (eIF-4G) which links 5 ́ cap and 3 ́ poly – A 
binding proteins. The end product of (-)-DNA synthesis is a unit length DNA 
copy of the pgRNA from its 5 ́ end to the UUCA motif in the 3 ́ DR1* Figure 
10A; hence it contains a small, about 10 nt, terminal redundancy (“r”). Most of 
the pgRNA template is degraded concomitantly to (-)-DNA synthesis by the 
RNase H domain of P. The fate of the non – copied 3 ́ end of the pgRNA from 
DR1* to the poly – A tail is not exactly known. The 5 ́ terminal about 15 to 18 nt 
of the pgRNA including the 5 ́ DR1 sequence are spared from degradation. This 
capped 5 ́RNA oligo is essential as primer for (+)-DNA synthesis. Extension of 
the RNA from its original position (“in situ priming”) gives rise to a double – 
stranded linear (dsL) DNA Figure 10E which occurs to a small percentage in all 
hepadnaviruses (Staprans et al., 1991). For rcDNA formation, the RNA primer 
must be transferred to the 3 ́ proximal DR2 Figure 10B. Why the RNA primer 
predominantly jumps to DR2 although its complementarity to the initial site is 
larger is not obvious. From its new location on DR2 the RNA primer is extended 
towards the P bound 5 ́ end of the (-)-DNA, including the 5 ́r redundancy. Further 
elongation requires a third template switch, i.e. circularization Figure 10C. In 
effect, the growing (+)-DNA end is transferred from 5 ́ r to 3 ́ r on the (-)-DNA 
template from where it can further be extended to yield rcDNA Figure 10D. 
Though sequence identity between 5 ́ r and 3 ́ r is important, additional cis – 
elements are again required to ensure efficient RNA primer translocation and 
circularization. The Loeb laboratory has defined several such cis – elements on 
the (-)-DNA (Habig and Loeb, 2003); (Liu et al., 2004); (Mueller-Hill and Loeb, 
2002), e.g. 3E, M, and 5E, which are located at both termini and in the middle of 
pgRNA.  
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Figure 10 RCDNA formation. A: (-)-DNA completion. The DNA primer, still linked to 
TP, is extended from DR1* to the 5´ end of pgRNA. The RNA is simultaneously 
degraded by the RH domain, except for its capped 5´ terminal region including 5´ DR1; 
the fate of the poly – adenylated  3´ end is unclear; B: RNA primer translocation (second 
template switch). The RNA primer translocates to DR2, and is extended to the 5´ end of 
(-)-DNA. 3´ r and 5´ r denote an about 10 nt redundancy on the (-)-DNA. As above, 
several cis – elements appear to promote close proximity of the DR1 donor and the DR2 
acceptor, as schematically indicated in the right hand Figure; C: Circularization (third 
template switch). Having copied 5´ r, the growing 3´ end of the (+)-DNA switches to 3´ r 
on the (-)-DNA, enabling further elongation. This reaction must involve juxtaposition of 
5´ r and 3´ r. For easier comprehension, the switch is also depicted on the basis of the 
representation shown on the right of Figure 10B; both are topologically equivalent; D: 
RCDNA. Extension on the (-)-DNA template creates a set of (+)-DNA strands of various 
length; E: Double – stranded linear (dsL) DNA. This minor DNA form originates when 
the RNA primer, having failed to translocate to DR2, is extended from its original 
position ("in situ priming"). 
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CAPSID MATURATION 
HBV nucleocapsid formation starts when the complex of the RNA pregenome, 
HBV polymerase and HBcAg dimers has formed (Bartenschlager and Schaller, 
1992); (Junker-Niepmann et al., 1990). When nucleoapsid assembly is completed, 
the conversion of the RNA into single – stranded and then into partially double – 
stranded DNA takes place. In contrast to the nucleocapsids isolated from secreted 
virus, that contain only mature partially double – stranded DNA, intracellular 
nucleocapsids show all these different stages of the viral DNA synthesis. Based 
on these observations, it was concluded that the early RNA – containing capsids 
(the immature nucleocapsid) are not incorporated in to viral particles 
(Gerelsaikhan et al., 1996). Detailed analyses revealed that capsid maturation is 
associated with a dephosphorylation of the nucleocapsid. Phosphorylation is 
required for efficient RNA packaging. In vitro experiments in HepG2 cells 
revealed that Ser-162 in the HBV core protein is necessary and sufficient for the 
encapsidation of HBV RNA. However, both Ser-162 and Ser-170 are required for 
the production of HBV DNA replicative intermediates. The core Ser-155 is 
essential for the formation of relaxed circular DNA intermediates (Liao and Ou, 
1995). Based on the data from the HBV (Roseman et al., 2005) and DHBV 
(Basagoudanavar et al., 2007) systems, it has been concluded that nucleocapsid 
maturation can be described by a sequential phosphorylation (immature 
nucleocapsid) and dephosphorylation (mature nucleocapsid) (Roseman et al., 
2005). This dephosphorylation during capsid maturation is associated with 
significant differences in the structure between the RNA- and the DNA- 
containing cores.  
ENVELOPMENT AND BUDDING  
The envelopment of the mature nucleocapsid strictly depends on the presence of 
the viral surface proteins. Formation of LHBs and SHBs are strictly required. 
Moreover, virion formation requires that in a fraction of LHBs the PreS1 PreS2 
domain faces the cytoplasm (Bruss and Ganem, 1991). To identify nucleocapsid 
residues that are crucial for envelopment, a variety of natural and engineered 
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mutants were analyzed. Based on these experiments, it was concluded that the 
spike tip seems to have no impact on the capsid envelopment (Ponsel and Bruss, 
2003). Cryo – electron microscopy of HBV particles supports the observation that 
the spike tip interacts via electrostatic interactions with HBsAg (Seitz et al., 
2007). Mature hepadnaviral nucleocapsids form in the cytoplasm. For DHBV, it 
has been shown that mature nucleocapsids attach to intracellular membranes. This 
attachment does not require the presence of envelope proteins. Immature 
nucleocapsids do not bind (Mabit and Schaller, 2000). The exact mechanism that 
mediates the delivery of mature nucleocapsids to the post – ER, pre – Golgi – 
compartment (Huovila et al., 1992), where envelopment occurs, is presently not 
understood. Inhibition of different MVB (multivesicular bodies) proteins. revealed 
that MVB functions are required for efficient budding and release of enveloped 
HBV virions. Moreover, HBV virions and subviral particles are all released by 
distinct pathways with separate host factor requirements (Watanabe et al., 2007).  
NATURAL HISTORY OF HBV INFECTION 
The natural history of chronic HBV infection Figure 11 in individuals is complex, 
and infected persons can pass through several phases. Patients can move from a 
state of high viral load and no liver disease to one of active liver disease, followed 
by inactive disease, and then revert back to active liver disease years later. 
Progression to advanced fibrosis can be rapid, slow, or sporadic. During the 
inactive periods, hepatic inflammation, fibrosis, and even early cirrhosis can be 
reversed over time only to reappear again if the disease reactivates. Thus, chronic 
hepatitis B is a dynamic condition and it is difficult to predict what will happen 
over time to an individual with this chronic infection (McMahon, 2009b).  
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Figure 11: Phases of HBV infection 
 
ACUTE INFECTION 
In acute HBV infection, hepatitis B surface antigen (HBsAg) becomes detectable 
in the serum after an incubation period of 4 to 10 weeks, followed shortly by the 
appearance of antibody against the hepatitis B core antigen, which is 
predominantly of the IgM isotope in the early phase (Hoofnagle et al., 1981). 
Levels of HBV DNA are generally very high, frequently in the range of 200 
million IU/mL to 200 billion IU/mL (10 9010 12 copies/mL) (Ribeiro et al., 
2002). Circulating HBeAg can be detected in most patients with acute HBV 
infection, and these patients can readily transmit the infection (Koff et al., 1977) 
Figure 12. Aminotransferase levels do not increase until after viral infection is 
well established because time is required for specific cytotoxic T lymphocyte 
responses to develop against virally infected hepatocytes. Approximately 30% to 
50% of infected adults present with an icteric illness after an incubation period of 
6 weeks to 6 months (McMahon et al., 1985). The outcome of acute HBV 
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infection depends on age and immune competence at the time of infection.). For 
example, chronic HBV infection will develop in as many as 90% of infected 
neonates and infants but only in 1% to 5% of immunocompetent adults (excluding 
those with acute exacerbations of chronic HBV infection). Children aged 1 to 5 
years have an intermediate risk (approximately 30%) (Tassopoulos et al., 1987); 
(Beasley et al., 1982). Most persons with acute HBV infection are adults. As a 
rule, acute HBV infection resolves without the need for intervention or antiviral 
treatment. Fulminant hepatitis occurs in 0.1% to 0.5% of those with acute HBV 
infection and often demonstrates no evidence of HBV replication because of the 
massive immune – mediated lysis of infected hepatocytes (Wright et al., 1992). In 
endemic areas, exposure to HBV at birth or in early childhood results in higher 
rates of chronic HBV infection. Persons infected as children may present in 
adulthood with clinical manifestations similar to those of acute hepatitis if they 
have acute exacerbation of chronic HBV infection. These exacerbations 
frequently may be associated with elevated levels of IgM antibody to hepatitis B 
core antigen, which may lead to misdiagnosis of acute HBV infection (Liaw et al., 
1985) and an increase in the serum α-fetoprotein concentration, which may raise 
concerns for the presence of hepatocellular carcinoma (HCC) (Lok and Lai, 
1989). Thus, it is important to define and understand the phases of acute and 
chronic HBV infection. Hepatitis B virus was thought to be cleared completely in 
those who recover from acute HBV infection. However, with the development of 
sensitive assays for HBV DNA detection, traces of the HBV genome have been 
frequently identified in the liver or serum up to 10 years after clinical recovery 
from  acute  HBV  infection,  despite  the  disappearance  of  viral  antigens  and 
the appearance of antiviral antibodies and specific cytotoxic T lymphocytes 
(Rehermann et al., 1996). These observations suggest that HBV is rarely 
completely eradicated after recovery from acute infection, which may account for 
several reports of reactivation of HBV replication in persons with serologic 
markers of recovery from HBV who receive chemotherapy or immunosuppression 
after organ transplantation (Blanpain et al., 1998).  
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Figure 12: HBV serum markers during acute infection  
 
 
PHASES OF CHRONIC HBV INFECTION 
Those with chronic HBV infection may present: 1. in a state of immune tolerance, 
2. with HBeAg- positive chronic hepatitis, 3. as an inactive HBsAg carrier, or 4. 
with HBeAg-negative chronic hepatitis Figure13.  
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Figure 13: Phases of chronic hepatitis B virus infection. White arrows represent 
changes of histopathology, whereas gray arrows represent the changes in serologic 
markers between phases. Up- and down-facing arrows represent an increase or decrease 
of DNA level (↑= low increase; ↑↑= moderate increase; ↓↓= moderate decrease; ↑↑↑= 
high increase). ALT= alanine aminotransferase; HBeAg= hepatitis B e antigen. 
 
Phase 1: Immune Tolerance  
HBV – infected persons in the immune tolerant phase are HBeAg – positive, have 
normal ALT levels, and elevated levels of HBV DNA that are >20,000 IU/mL and 
commonly well above 1 million IU/mL. The immune tolerant phase is thought to 
occur most frequently in persons who are infected via perinatal transmission from 
HBeAg – positive mothers (Livingston et al., 2007). HBeAg may act as an 
immune tolerant protein that aids the virus in avoiding detection by the immune 
system. In immune competent persons, HBV is not cytopathic and hepatocellular 
damage is induced by the host immune system's efforts to eliminate HBV. The 
immune tolerant phase can last for a few years to more than 30 years (Hui et al., 
2007). During this phase, there is either no or minimal liver inflammation or 
fibrosis. However, because the HBV polymerase gene has reverse transcriptase 
properties, HBV integrates randomly into the host's hepatocyte DNA and during 
the immune tolerant phase, persistently high levels of HBV DNA over many years 
would likely mean an accumulation of integration sites, increasing the risk of 
HCC over time even in the absence of active liver inflammation and fibrosis.  
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Phase 2: HBeAg – Positive Chronic Hepatitis   
As the host immune system matures and begins to recognize HBV – related 
epitopes on hepatocytes, immune – mediated hepatocellular injury ensues. 
Although HBV replication continues in the liver and viremia is continual, the viral 
level in the serum becomes lower than during theimmune tolerance phase when 
viral replication is completely unopposed (Tedder et al., 2002). The immune 
active phase, also sometimes referred to as the “chronic hepatitis B phase” or the 
“immune clearance phase”, is characterized by elevated ALT levels and an 
elevated HBV DNA level above at least 2000 IU/mL and histological findings of 
active inflammation and often fibrosis in the liver (Liaw et al., 1988). Most 
patients with HBeAg – positive chronic hepatitis remain asymptomatic. However, 
some patients present with a symptomatic flare of hepatitis that mimics acute 
hepatitis or even with fulminant hepatic failure (Davis et al., 1984). Spontaneous 
HBeAg seroconversion, which occurs annually in as many as 10% to 20% of 
those with HBeAg – positive hepatitis, is an important landmark in the natural 
history of chronic HBV infection (Hoofnagle, 1981). Factors associated with a 
higher rate of spontaneous HBeAg seroconversion include older age, higher 
aminotransferase levels and certain HBV genotypes (Yuen et al., 2003); (Chu et 
al., 2002). In contrast, spontaneous HBeAg clearance or seroconversion occurs in 
fewer than 5% of patients with normal or mildly elevated levels of alanine 
aminotransferase (ALT) (Ribeiro et al., 2002). Many HBeAg – positive persons 
undergo seroconversion over time. However, those who remain HBeAg positive 
continue to be at risk for progressive liver disease. Approximately 12% to 20% of 
them will develop serious liver injury that results in cirrhosis and complications 
within 5 years (Liaw et al., 1988); (Fattovich et al., 1991) depending on the 
duration of the chronic hepatitis and the frequency and severity of flares 
(McMahon et al., 2001). In a small proportion of patients with HBeAg – positive 
chronic hepatitis B, HCC may develop without cirrhosis. Although this 
phenomenon is widely recognized among clinicians, the rate at which it occurs is 
low (Liaw et al., 1986).  
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Phase 3: Inactive HBsAg Carriers  
After seroconversion, most patients remain negative for HBeAg and positive for 
anti – HBe antibody. Seroconversion is usually accompanied by stabilization of 
hepatitis, characterized by normalization of ALT levels and decreases in HBV 
DNA to low (<1000 copies/mL) or undetectable levels, depending on the assays 
used. This condition is commonly referred to as the "inactive carrier state" (Lok et 
al., 2001). Histologically, minimal to mild hepatitis may be observed, although 
the degree of fibrosis may be variable. For example, inactive cirrhosis may be 
identified in patients who had severe liver injury before  seroconversion (Yim and 
Lok, 2006). Most patients remain in this phase for many years, if not indefinitely 
(de Franchis et al., 1993). Their prognosis is generally favorable, particularly if 
this phase is reached early in the disease course. Unlike patients with continued 
active viral replication, most inactive carriers do not have progressive liver 
disease. Hepatitis B e antigen reversion occurs in a minority of patients who have 
seroconversion (McMahon, 2004). Spontaneous clearance of HBsAg was delayed 
in a small number of inactive HBV carriers, at the estimated annual rate of 0.5% 
to 2% in Western countries and at a much lower rate of 0.1% to 0.8% in Asian 
countries. Patients with delayed spontaneous clearance of HBsAg are thought to 
have a favorable prognosis (i.e., lack of progression to cirrhosis) (Liaw et al., 
1991); (Alward et al., 1985); (Chen et al., 2002).  
Phase 4: HBeAg – Negative Chronic Hepatitis  
Chronic hepatitis may recur in up to one third of inactive HBV carriers without 
reversion of HBeAg in their serum (Sung et al., 2002). Most patients progress to 
this phase after a variable length of time in  the inactive HBV carrier state, 
whereas some progress to HBeAg – negative chronic hepatitis directly from  
HBeAg – positive chronic hepatitis (Hsu et al., 2002). This phase is characterized 
by the absence of HBeAg, the presence of anti – HBe antibody, detectable levels 
of HBV DNA, elevated levels of serum ALT, and histological findings of 
continued necroinflammation of the liver (Hadziyannis and Vassilopoulos, 2001). 
Compared to those with HBeAg – positive chronic hepatitis, patients with HBeAg 
– negative chronic hepatitis are generally older, have more advanced disease as 
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evidenced by liver histology, and have lower serum HBV DNA levels (Yim and 
Lok, 2006). The natural course of HBeAg – negative chronic hepatitis B is 
incompletely understood. In some patients, disease may progress silently for 
years, escaping clinical recognition. In such patients, serum HBV DNA levels 
may increase only transiently before serum ALT levels increase (Hadziyannis and 
Vassilopoulos, 2001). In general, HBeAg-negative chronic hepatitis represents a 
potentially severe and progressive form of chronic liver disease (Lai et al., 1994). 
Because most, if not all, of these patients have gone through the HBeAg – positive  
chronic hepatitis phase, varying degrees of hepatic fibrosis are already present (Di 
Marco et al., 1999). Moreover, continued hepatitis activity (persistent or 
intermittent) in the absence of spontaneous, sustained remission further increases 
the risk of progressive fibrosis. Spontaneous clearance of HBsAg is  rare 
(Papatheodoridis et al., 2001). 
OCCULT HBV INFECTION  
Occult HBV infection is defined as the existence of HBV DNA in serum, 
although it is not considered as a phase of CHB (Torbenson and Thomas, 2002). 
A 2008 international workshop on occult hepatitis B virus (Yang et al.) infection 
(OBI), endorsed by the European Association for the Study of the Liver EASL 
(Raimondo et al., 2008b), as well as The Taormina Consensus Conference in 
2008, defined “OBI” as the “presence of HBV DNA in the liver of individuals 
testing HBsAg – negative with currently available assays” (Raimondo et al., 
2008a) and introduced a cutoff value for serum HBV DNA (< 200 IU/mL). In 
addition to a symptomatic and serologically evident infection, occult persistent 
HBV carriage has been identified since nucleic acid amplification assay enhances 
its sensitivity to hepadnaviral genomes and their replicative intermediates. There 
is evidence that occult HBV infection is a common and long – term consequence 
of acute hepatitis B resolution. This form of residual infection is termed as 
secondary occult infection (SOI) (Mulrooney-Cousins and Michalak, 2007). 
Several possible mechanisms have been hypothesized for the pathogenesis of OBI 
and the condition is probably multifactorial. Both host and viral factors are 
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important in suppressing viral replication and keeping the infection under control 
(Hollinger and Sood, 2010). It was suggested that long – term maintenance of an 
active  anti – viral T cell response several years after clinical recovery from acute 
hepatitis B could be important, not only for protection against reinfection, but also 
for keeping the persisting virus under tight control where detection of minute 
amounts of virus in some recovered subjects was confirmed (Penna et al., 1996). 
Humoral and cellular immune pressure on the HBV envelope proteins are major 
mechanisms generating OBI. Masking of HbsAg by HbsAg – anti – HBs immune 
complexes is another postulated mechanism for the development of OBI (Hu, 
2002). The severe consequences of occult HBV infection have not been fully 
recognized. There is evidence that occult HBV can be a source of virus 
contamination in blood and organ donations, as well as a reservoir from which full 
blown hepatitis can arise (Schreiber et al., 1996). Case reports also indicate that 
immunosuppression caused by chemotherapy or immunomodulatory agents or 
immunodeficiency due to HIV infection or hematological malignancies can 
induce reactive occult infection (Hui et al., 2006); (Chamorro et al., 2005).  
cccDNA DURING THE NATURAL HISTORY OF CHRONIC 
HEPATITIS B  
Chronic infection is believed to be maintained by a replicative form of HBV DNA 
termed cccDNA. During infection, HBV cccDNA accumulates in cell nuclei 
where it persists as a stable episome and acts as a template for the transcription of 
viral genes (Tuttleman et al., 1986); (Newbold et al., 1995).  Considering the long 
half – life of hepatocytes, the limiting factor in eliminating infection is thought to 
be the clearance of cccDNA reservoirs from infected cells (Moraleda et al., 1997); 
(Mason et al., 1980). Three immune mechanisms have been proposed to mediate 
cccDNA clearance. In the first scenario, cccDNA is primarly eliminated by 
cytokines and cell death or cell proliferation do not contribute significantly (the 
cure model). In the second, cytokines suppress cytoplasmic viral replication and 
new cccDNA formation but do not act on pre – existing cccDNA that is 
eliminated by both cell death  and mitotic loss and would need a turnover of 
approximately 0,7 of the total liver mass (The "death and  compensatory 
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proliferation" model). In the third, cccDNA survives hepatocytes mitosis, is 
distribuited in a binomial fashion to the progeny hepatocytes and it is eliminated 
only by the elimination of infected cells, requiring an estimated turnover 
exceeding 2,5 times the total liver mass (the "cell death" model) (Mason et al., 
1980). There is evidence from animal models supporting each mechanism, and 
while these mechanisms are not mutually exclusive, it is currently unclear how 
infection is resolved in patients. To gain insight on the persistence of cccDNA and 
clearance mechanisms, Werle-Lapostolle et  al. studied patients in different phases 
of the natural history of CHB and a group of patients participating in a placebo – 
controlled trial of the nucleotide analog adefovir dipivoxil. Intrahepatic cccDNA 
levels in patients with hepatitis B e antigen positive (HBeAg+) CHB (1.4 
copies/cell) were significantly higher than in HBeAg – patients (0.01 copies/cell; 
P<0.001), or inactive carriers (0.02 copies/cell; P<0.001) (Werle-Lapostolle et al., 
2004). Patients with evidence of hepatitis B surface antigen (HBsAg) clearance 
had extremely low levels of cccDNA (0.002 copies/cell; P<0.001, compared to 
HBeAg+ patients). Similarly, median total intracellular HBV DNA levels in 
HBeAg+ patients (155 copies/cell) were significantly higher compared to HBeAg-
patients (0.6 copies/cell; P<0.001), inactive carriers (2 copies/cell) (P<0.001), and 
HBsAg-patients (0.19 copies/cell; P<0.001). This result is consistent with 
observations of greater levels of serum HBV DNA in HBeAg+ patients 
(compared to the later groups). The observation that cccDNA remained detectable 
in all HBeAg – patients explains why viral reactivation has been observed, to 
varying frequencies, in all these patient groups.  
SEQUELAE OF CHRONIC HBV INFECTION 
Cirrhosis  
Individuals with chronic HBV infection are at an increased risk of developing end 
– stage liver diseases including cirrhosis, hepatic failure, and HCC. The annual 
incidence of cirrhosis in patients with HBeAg – negative chronic hepatitis may be 
as high as 8% to 10%, compared with 2% to 5% in those with HBeAg – positive 
chronic hepatitis (Liaw et al., 1988) The higher rate of cirrhosis in patients 
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presenting with HBeAg – negative chronic hepatitis, a late phase in the natural 
history of chronic HBV infection, is not surprising because these patients tend to 
be older and have more advanced liver disease (Fattovich, 2003). In addition to 
HBeAg status, HBV genotype and high levels of HBV replication have been 
found to  affect the natural history of HBV infection (Iloeje et al., 2006); (Sumi et 
al., 2003). Hepatitis B virus DNA levels were the strongest predictor of 
progression to cirrhosis in a multivariable regression model. In addition, HBeAg 
positivity (HR, 1.7; 95% CI, 1.2-2.3), abnormal ALT levels (ALT>45; HR, 1.5; 
95% CI, 1.1-2.1), male sex, and increasing age were associated with increased 
risk of cirrhosis (Iloeje et al., 2006). Additional risk factors associated with 
progression to cirrhosis include habitual alcohol intake102 and concurrent 
infection with hepatitis C or D virus (HCV, HDV) or human immunodeficiency 
virus (Liaw et al., 2004); (Thio et al., 2002).   
Hepatocellular carcinoma  
It has recently been estimated that about 53% of HCC cases in the world are 
related to HBV infection. The lifetime risk of developing HCC is increased even 
in patients with cleared HBsAg or occult HBV infection. Further risk factors 
include chronic HCV infection, exposure to aflatoxin B1, alcohol abuse, obesity 
and diabetes (Lupberger and Hildt, 2007). Thus, it is important to identify HBV-
infected patients at a higher risk of progressing to HCC. The reason why some 
CHB patients progress to HCC remains unknown. Host factors, such as immune 
response to HBV, genetic predisposition to HCC, high HBV replication rate, 
mutations within the HBV genome, are related with HCC. Many observations 
revealed that the major factor for the development of HBV-associated HCC is the 
immune system (Ganem and Prince, 2004). The same T – cell  response has 
different effects. If T – cell response is  strong enough, HBV can be eliminated 
from the liver. If not, a pro – carcinogenic effect can be induced by triggering 
necrotic inflammatory disease without final eradication of HBV from the liver. It 
can, thus, be concluded that the immune system – mediated chronic inflammation 
of the liver, continuous cell death and subsequent cell proliferation may increase 
the frequency of genetic alteration and the risk of  developing cancer. However, 
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the molecular basis of inflammatory liver carcinogenesis caused by HBV remains 
largely unsolved. Cytokines modulate inflammation and the presence of 
inflammatory cells with the production of inflammatory cytokines activates 
cellular oxidant-generating  pathways. Reactive oxygen species that are generated 
in inflammatory conditions induce oxidative DNA damage and increased 
oxidative stress caused by chronic inflammation can produce genetic mutations 
and chromosomal alterations (Coussens and Werb, 2002). HBV genotype C 
infection is associated with a higher risk of developing HCC than HBV genotype 
B infection (Kakimi et al., 2002). The BCP A1762T/G1764A mutant is associated 
with an increased risk of developing HCC compared with the double wild type 
variant, whereas the precore G1896A mutation is associated with a decreased risk 
of developing HCC compared with the wild – type variant. Several mechanisms 
of liver carcinogen are related to the BCP A1762T/G1764A mutation which may 
enhance HBV virulence by increasing host immune response and viral replication, 
or by altering the coding region of the X antigen. Mutant BCP may augment the 
host immune response to HBV – infected hepatocytes by diminishing circulating 
HBeAg and increasing hepatocyte apoptosis and regeneration, thus leading to 
liver injury (Tong et al., 2007). The BCP mutation appears to enhance the efficacy 
of viral replication either by modulating the relative levels of precore and core 
RNAs or by creating a transcription factor binding site for hepatocyte  nuclear 
factor 1. Mutations in the BCP region over lapping the coding sequence of the X 
antigen of HBV may result in changes of amino acids, K130M and V131I, in the 
X gene. These  amino acid changes may interfere with cell growth control and 
DNA repair, thus leading to HCC (Yang et al., 2008). There is experimental 
evidence that HBx, a multifunctional protein with oncogenic potentials, can 
interact with a large number of cellular factors and modulate their normal 
function, thus leading to deregulation of normal cell activities and HCC (Hagen et 
al., 1994). Despite its importance in HCC development, the clinical significance 
of genetic variability in the x genetic region still remains poorly understood 
(Bouchard and Schneider, 2004).  
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DEFINITION OF HBV – CURE  
The term “cure” has been used recently in HBV – infected patients in a somewhat 
confusing way and needs clarification. Loss of HBsAg with or without 
seroconversion to anti – HBs antibodies is believed to be an effective end point of 
resolved acute HBV or of antiviral treatment in chronic HBV where antiviral 
treatment can be stopped ("functional cure"). It represents in general the end of 
detectable viral replication in the serum with sustained immunological control of 
persistent cccDNA in the liver of infected individuals. This is clearly different 
from "sterilizing cure" which, for HBV, would imply the eradication of all HBV – 
DNAs, including the viral template in the nucleus of infected hepatocytes, 
cccDNA. "Clinical" or "functional cure" implies a remaining risk that 
transcriptionally inactive cccDNA may become active again under certain clinical 
conditions, such as immunosuppression. True eradication of cccDNA remains an 
elusive therapeutic goal, but will be pursued intensively with new drugs in the 
coming years (Dandri and Petersen, 2016). It is important to underline that even if 
a "sterilizing cure" with complete elimination of cccDNA will be achieved, 
HBsAg might be still detectable, due to its cccDNA-independent production from 
integrated HBV sequences. Notably, functional cure of HBV with HBsAg loss 
might be sufficient to clear HDV infection, because HDV cannot replicate in the 
absence of HBsAg (Petersen et al., 2016). 
ACHIEVEMENTS AND LIMITS OF CORRENT HBV THERAPIES  
Currently approved regimens include two classes of antivirals: 1) Nucleos(t)ide 
analogs (NAs), and 2) Interferon alpha2a, usually in its pegylated form (PEG – 
IFN). NAs do not affect the transcriptional activity of the cccDNA (Dandri and 
Locarnini, 2012); (Nguyen and Locarnini, 2009) numerous clinical studies have 
reported a significant decrease in cccDNA levels (Werle-Lapostolle et al., 2004); 
(Sung et al., 2005); (Wong et al., 2006); (Lutgehetmann et al., 2008); (Wursthorn 
et al., 2006), but long – term antiviral therapy is needed to achieve significant 
reduction of the cccDNA pool (Dandri and Locarnini, 2012). Moreover, entecavir 
(ETV) and tenofovir (TDF), the two current first line NAs, only modestly affect 
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the levels of serum HBsAg (Brunetto et al., 2009) and immunological control is 
rarely achieved, making such treatments a life time commitment, especially in 
HBeAg-negative patients. Interestingly, transitory hepatic flares after stopping 
long – term nucleoside therapy facilitate recognition and destruction of HBV – 
infected cells (Hadziyannis et al., 2012) and cell killing occurring during hepatic 
flare would further contribute to reduce cccDNA and viral antigen levels, both of 
which may be instrumental to gain immunological control. Nevertheless, stopping 
long – term NA therapy in the presence of HBsAg is currently not an approved 
therapy – only in areas of the world with budget restrictions it is being considered 
to stop NA treatment in the presence of HBsAg after more than 12 months of 
undetectable HBV – DNA. Moreover, recent studies indicated that NA – 
treatments are not able to eliminate the risk of developing hepatocellular 
carcinoma (Arends et al., 2015). Thus, there is an urgent need to develop 
therapeutic concepts leading to loss of HBsAg and, ideally, seroconversion to anti 
– HBs antibodies in a much larger proportion of individuals.  
COMBINING PEG – IFM AND NAs – SIMULTANEOUSLY  
Emerging data support a small but definite clinical benefit associated with 
combination therapy using both NA plus PEG – IFN. The intention is to harness 
both direct antiviral and immunomodulatory mechanisms. Clinical trials have 
evaluated de novo combination, as well as add-on or switch strategies (Dandri and 
Petersen, 2016).  In one of the first studies to evaluate combination therapy, 
patients were treated for 1 year simultaneously with adefovir plus PEG – IFN. 
Stronger HBV suppression with approximately 2-log cccDNA reduction and 99% 
inhibition of intrahepatic virion productivity was observed, suggesting a 
synergistic function (Lutgehetmann et al., 2008); (Wursthorn et al., 2006). 
Unfortunately, in this study a PEG – IFN monotherapy control arm was missing. 
Significantly greater decreases in HBV DNA were achieved with ETV add-on on-
treatment, but were not sustained posttreatment. Moreover, a recent study reported 
unexpected severe peripheral neuropathy in some patients who received 
combination therapy of PEG – IFN and telbivudine, compared to patients who 
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received telbivudine alone (Marcellin et al., 2015).  The study was terminated 
early because of safety concerns, indicating that in depth safety studies must be 
performed in ongoing combination trials. Switching treatment from NAs to PEG – 
IFN might be another treatment option to induce higher rates of HBsAg loss 
(Ning et al., 2014). For Hepatitis B and Delta co – infection or superinfection, the 
results of combining PEG – IFN with NAs were disappointing. There was neither 
an extra benefit in combination therapy nor in extension of treatment duration to 
two years, compared to one year of PEG – IFN monotherapy (Rizzetto, 2016). 
Combining drugs with the same virological target, such as different NAs, may not 
have additive therapeutic effects. Therefore, EASL HBV CPG is considering 
combination therapy of potent NAs only as rescue therapy under highly selected 
circumstances such as occurrence of multi – resistant virus strains, and the 
number of published studies involving this segment of patients is very limited. To 
date, combination treatment strategies cannot be recommended, neither for HBV 
monoinfection, nor for HBV/HDV coinfection (Petersen et al., 2016). EASL 
considers combination therapy in CHB to be an area requiring further research 
and supports further assessment of the safety and efficacy of the combination of 
PEG – IFN with potent NAs to increase anti – HBe or anti – HBs seroconversion 
rates.  
NOVEL ANTIVIRAL STRATEGIES  
Several strategies targeting HBV entry, HBV cccDNA production and processing, 
viral replication and viral protein expression are currently being explored Figure 
14; Table 1. The discovery of the sodium taurocholate co – transporting 
polypeptide (NTCP) as the main receptor for HBV entry has been a major 
breakthrough for the HBV field. The identification of NTCP has allowed the 
establishment of cell lines susceptible to HBV infection in which the complete 
viral life – cycle, including the cccDNA mini – chromosome, can be studied thus 
enabling new research possibilities and drug discovery efforts (Petersen et al., 
2016).  
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Figure 14: New anti – HBV approaches. A graphical representation of the drug target 
points within the HBV life – cycle. Adapted from (Chan et al., 2011).  
 
 
 
55 
 
 
 
Table 1: Drug candidates targeting specific points in the HBV life – cycle. Strategy 
numbers refer to numerical points shown graphically in Figure 14.  
 
Entry Inhibitors  
In the setting of CHB, the rationale of HBV and HDV entry inhibitors is to impair 
viral propagation and, in the presence of ongoing liver damage and regeneration, 
to allow the expansion of uninfected hepatocytes and cure of HBV and HDV 
infection (Volz et al., 2013); (Urban et al., 2014). Cyclosporine A, that 
irreversibly binds NTCP, and the cholesterol absorption inhibitor ezetimibe, that 
act as a transport substrate for NTCP, both inhibit HBV/HDV entry in cell culture 
models but, although licensed for other clinical settings, have not so far been 
tested in vivo against HBV (Urban et al., 2014). A number of small molecule 
compounds have been identified in functional screenings for HBV-entry 
inhibition (Watashi, 2015); (Tsukuda et al., 2015) and are currently in early pre-
clinical evaluation. Myrcludex B, a myristylated PreS1 peptide that competes with 
HBV/HDV for binding to NTCP has been shown to prevent HBV/HDV entry in 
vitro and in vivo and to impair viral dissemination when administered post-
inoculation in human liver- chimeric uPA/SCID mice (Petersen et al., 2008); 
(Lutgehetmann et al., 2012). The future role for Myrcludex B remains unclear due 
to the limited efficacy as monotherapy for HBV and the impact on bile acids 
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metabolism advice for caution in planning long – term treatments with Myrcludex 
B (Xinfeng, 2015). Myrcludex B must be explored in several further combination 
regimens to improve efficacy against HBV. More interesting are the results in 
HBV/HDV co – infected patients, who have very limited therapeutic options and 
might benefit from further exploration of Myrcludex B in combination therapies 
provided that long – term safety issues are clarified. NTCP co – receptors have 
been identified, including Heparan Sulfate Proteoglycans (HSPGs) and, more 
recently, Glypican 5 (Verrier et al., 2016) but their potential value as new targets 
for HBV entry inhibition strategies remains to be established.  
Targeting cccDNA  
Strategies targeting the cccDNA for HBV cure aim at preventing cccDNA 
formation, eliminating existing cccDNA or silencing cccDNA transcription. 
Mechanistically, control of cccDNA can be obtained, in principle, by capsid 
disassembly, inhibition of rcDNA entry into nucleus, inhibition of conversion of 
rcDNA to cccDNA, physical elimination of cccDNA, inhibition of cccDNA 
transcription (epigenetic control), or inhibition of viral/cellular factors 
contributing to cccDNA stability/formation. These objectives can be achieved by 
direct – acting antivirals (DAAs), or host-targeting agents (HTAs), that inhibit key 
host factors required for the viral life cycle, and immune – modulatory agents, that 
elicit signals converging on the cccDNA mini – chromosome. All these 
approaches are currently at the preclinical stage. An important limitation is 
represented by the lack of standardized assays for specific cccDNA quantification 
in cells and tissues. Moreover, direct methods to discriminate between active and 
inactive cccDNA pools and suitable surrogate markers for cccDNA activity to 
treatment efficacy assessment in trials and clinical practice are needed.  
a) cccDNA formation. The precise mechanisms and the viral/cellular players 
involved in the conversion of rcDNA into cccDNA, the critical step for both the 
establishment of HBV infection after viral entry and the replenishment of the 
cccDNA pool from mature capsids re – cycling to the nucleus, are still unknown. 
TDP2 mediates the first step of cccDNA formation from incoming rcDNA 
(Koniger et al., 2014) but its role in the formation of active cccDNA precursors 
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has been challenged (Cui et al., 2015) and its value as a target for drug 
development remains to be established. Unbiased screenings led to identify di-
substituted sulfonamide (DSS) compounds as inhibitors of de novo cccDNA 
formation (Cai et al., 2012) but their molecular target is still unknown. New 
ongoing screening efforts in HBV – infected NTCP – HepG2   cells might identify 
new classes of cccDNA formation inhibitors.  
b) cccDNA silencing. cccDNA molecules in the nucleus are assembled with 
cellular histone proteins into chromatinized minichromosome and associate with 
the viral proteins HBx and HBc (Levrero et al., 2009). cccDNA transcription and 
HBV gene expression are controlled by the regulation of HBV chromatin and 
cccDNA-bound histone post – translational modifications (PMTs) (Levrero et al., 
2009); (Pollicino et al., 2006). HBx is critical for cccDNA transcription but not 
for cccDNA chromatinization or maintenance (Belloni et al., 2009); (Lucifora et 
al., 2011); (Riviere et al., 2015). Members of different classes of histone 
modifying enzymes have been shown to bind to and impact on cccDNA 
transcription. PEG – IFN, in addition to induce the expression of genes encoding 
intracellular or secreted proteins with direct or indirect anti – HBV properties, to 
activate natural killer (NK) and NKT cells and to destabilize viral nucleocapsids, 
has been shown to inhibit cccDNA transcription by decreasing cccDNA – bound 
histones acetylation (Belloni et al., 2012); (Liu et al., 2013). Modulation of the 
same enzymatic activities with small compounds has been shown to induce the 
expected PMTs on cccDNA bound histones, to reduce cccDNA transcription and 
to inhibit viral replication in cell systems, providing the proof of concept for an 
epigenetic silencing of cccDNA (Tropberger et al., 2015). However, its efficacy 
must be confirmed in vivo and the issues of functional redundancy between the 
members of the different classes of chromatin modifiers, the possible off-target 
effects on the host genome should be carefully considered. In this respect more 
selective approaches to affect cccDNA transcription and/or stability by targeting 
HBx, HBc and their host – interacting proteins (Belloni et al., 2012); (Liu et al., 
2013); (Benhenda et al., 2013); (Decorsiere et al., 2016); (Zlotnick et al., 2015) 
are actively pursued.  
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c) cccDNA destruction. Targeting cccDNA to destruction includes two different 
approaches. The first is based upon the ability, apparently shared by members of 
the IFN and TNF family of cytokines, to decrease cccDNA stability via the 
induction of deamination and apurinic/apyrimidinic site formation in the cccDNA 
and the up – regulation of nuclear APOBEC3 deaminases (Lucifora et al., 2014); 
(Xia et al., 2016). These results await confirmation and TNF – α and IFN – γ have 
little chances to be used as therapeutic agents. IFN – α activity on cccDNA 
stability at physiological or even pharmacological concentrations remains to be 
established in vivo. The safety and therapeutic index of antibodies activating the 
lymphotoxin – β receptor (LTβR) in patients with chronic HBV infection and liver 
disease remains to be explored. The second and more direct approach makes use 
of DNA cleavage enzymes delivered within viral vectors to target hepatocytes. 
These include homing endonucleases or meganucleases, zinc – finger nucleases 
(ZFNs) (Weber et al., 2014), transcription activator – like effector nucleases 
(TALENs) (Bloom et al., 2013) and, more recently, the clustered regularly 
interspaced short palindromic repeats (CRISPR)/CAS based – strategies (Kennedy 
et al., 2015a); (Kennedy et al., 2015b); (Ramanan et al., 2015); (Seeger and Sohn, 
2014). Most of the available results have been generated in cell models or after 
hydrodynamic injection of mice with both HBV DNA and CRISPR/CAS 
expression plasmids, resulting in an in vivo co – transfection of the mouse liver 
that mimicked an acute HBV infection rather then an established chronic HBV 
infection. Moreover, not all the cell models allowed a correct evaluation of the 
impact on cccDNA levels. Despite their great potential, a number of critical issues 
need to addressed before DNA cleavage approaches will be amenable to enter 
clinical development: a) proof of efficacy in relevant animal models of chronic 
HBV infection (i.e. immune – deficient humanized mice); b) evaluation of off – 
target effects; c) careful assessment of resistant viruses selection in vivo; d) 
potential targeting of integrated viral sequences and its consequences on viral 
pathogenesis and host genome stability.  
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Targeting HBV Capsids  
The HBV capsid is essential for HBV genome packaging, reverse transcription, 
intracellular trafficking and the re – import of encapsidated HBV genomes into 
the nucleus. The elucidation of the HBc crystal structure and the clarification of 
core dimers assembly process led to the development of several compounds that 
target HBc and capsid assembly and display anti – HBV therapeutic potential 
(Zlotnick et al., 2015). Since HBV capsid proteins can also traffic to the nucleus 
of infected cells, those compounds that are capable to target HBc nuclear 
functions, i.e. regulation of ISGs expression and/or regulation of cccDNA 
transcriptional activity, will have a great potential for enhanced antiviral activity 
(Petersen et al., 2016).  
The phenyl – propenamide derivatives AT – 61 and AT – 130 increase capsid 
assembly reaction rate (Delaney et al., 2002); (Feld et al., 2007), interfere with 
HBV RNA packaging and with the formation of apparently normal empty capsids 
(Feld et al., 2007); (Katen et al., 2010). It causes tertiary and quaternary structural 
changes without disrupting the capsid structure (Petersen et al., 2016); Figure 
15A.  
Despite their favorable toxicity profile this class of compounds has not been 
moved into clinical trials. Heteroaryldihydropyrimidines (HAPs) act as allosteric 
effectors to increase the kinetics of assembly, strengthen dimer – dimer 
association and prevent the proper formation of viral capsids (Deres et al., 2003) 
with the formation of aberrant core particles at high concentrations (Stray et al., 
2005); Figure 15B. In a short – term study in HBV – infected uPA/SCID human 
liver – chimeric mice Bay 41-4109 reduced HBV DNA by 1 log but HBV 
replication showed rebound soon after treatment cessation (Brezillon et al., 2011). 
Crystallographic studies indicate that HAP – 1 binds to a hydrophobic pocket at 
the dimer – dimer interface (Bourne et al., 2006), an observation that is supported 
by the generation of a HAP – resistant mutation of core protein, V124W, where 
the incorporated tryptophan partially fills the binding pocket and results in a 
protein that confers HAP – like activities (Tan et al., 2013). More recent studies in 
the optimization of the HAP series have focused on increasing potency (Wang et 
al., 2012); (Guan et al., 2015), aqueous solubility and the application of structural 
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constraints (Zhu et al., 2010). Structural elaboration of the peripheral functionality 
surrounding the HAP core identified GLS-4 (Wang et al., 2012). GLS-4 is 
reported to be more potent than BAY-41-4109 in vitro, demonstrating an EC50 of 
12 nM in stably transfected HepG2.2.15 cells (Wang et al., 2012), and in 
comparative studies measuring cell viability in primary human hepatocytes 
following treatment with increasing compound concentrations, GLS-4 
demonstrated no toxicity up to 25 mM, whereas BAY-41-4109 showed 60% 
toxicity at the same concentration (Wu et al., 2013). In vivo testing of GLS-4 in 
nude mice inoculated with HepAD38 cells showed a strong and sustained 
suppression of viral DNA (similar to that of BAY-41-4109) (Wu et al., 2013), and 
the compound is reported to be the subject of initial clinical evaluation in China 
(Zhou et al., 2013). Metabolite identification studies on BAY-41-4109 with 
mouse and human liver microsomes indicate that aromatization of the HAP core 
to the corresponding pyrimidine is the major metabolic pathway, and is consistent 
with the suboptimal pharmacokinetic profile that has been observed for HAPs. A 
recent study has focused on the chemical optimization of the series and the 
inclusion of a methyl group at the 4 - position of the dihydropyrimidine core to 
block aromatization, resulting in analogs with a significantly improved 
pharmacokinetic profile (Qiu et al., 2016). Morphothiadine mesilate (GLS4) is the 
first member of the HAP family of compounds that entered early clinical 
development. Phase I and II clinical trials have been conducted in China (Wang et 
al., 2012); (Zhou et al., 2013), but no clinical results have been reported to date. 
Studies have proded that for HAP-1 the strongest HAP density was located in the 
pocket of the C – subunit  (Bourne et al., 2006), whereas for AT – 130, the 
strongest density was in the B – subunit pocket. HAPs and phenyl – propenamides 
both synergize with NRTIs and are active against NRTI resistant strains in vitro 
(Delaney et al., 2002); (Billioud et al., 2011), highlighting the potential for 
combining capsid inhibitors with other antivirals.  
NVR 3-778, a member of the Sulfamoyl Carboxamide class of core – inhibitors, 
induces the misassembly of HBV core proteins in vitro and blocks the secretion of 
both infectious HBV DNA – containing virions and HBV RNA – containing 
particles by inhibiting pgRNA encapsidation in HBV replicating cells. NVR 3-
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778 antiviral activity is additive with NRTIs and other core – inhibitors in cell 
models and is conserved against all HBV genotypes from A to H and many NRTI 
– resistant strains (Petersen et al., 2016). In the humanized uPA/SCID mouse 
model, NVR 3-778 monotherapy for 6 weeks was superior to PEG – IFN and the 
combination of NVR 3-778 with PEG – IFN reduced serum HBV DNA below the 
limit of quantitation in all treated animals but without affecting intrahepatic 
cccDNA and pgRNA levels (Petersen et al., 2016). A phase 1a doseranging trial 
of orally administered NVR 3-778 in healthy adult volunteers [NVR3-778-101 
Protocol, Clinicaltrials.org # NCT02112799] showed a good safety and 
tolerability profile (Petersen et al., 2016). The phase 1b clinical trial enrolled 36 
HBeAg positive chronic hepatitis B adult naïve patients with serum HBV DNA > 
20,000 IU/ml and no history of clinical decompensation in 4 dosing cohorts [100, 
200, 400 mg QD and 600 mg BD] (Petersen et al., 2016). Safety and tolerability 
of NVR 3-778 was satisfactory for all cohorts, with no treatment – related 
discontinuations or serious adverse events with the exception of a severe hand and 
feet rash in one patient treated with the lowest dose. Significant HBV DNA 
reductions (1.72 log10, range 1.06-3.71 log10 IU/mL) were observed only with 
the 1200 mg (600 mg BD) daily dose (Petersen et al., 2016). Additional clinical 
trials are currently testing NVR 3-778 combination with PEG – IFN (Petersen et 
al., 2016) and higher NVR 3-778 doses as well as nucleoside combination 
regimens are planned. In an interim analysis, the combination of NVR 3-778 plus 
PEG – IFN led to some reduction of HBV DNA and HBeAg within the 
observation period of four weeks, but not to reduction of HBsAg (Petersen et al., 
2016). 
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Figure 
15: AT – 130 and 
HAP – 12 misdirect 
HBV capsid 
assembly and block HBV replication. Figure 15A. AT – 130 capsids are more  
“normalish” but inactive; Figure 15B. HAP – 12 leads to aberrant structures 
 
Inhibition of HBV gene expression  
Two main approaches have been developed to inhibit HBV gene expression at the 
post – transcriptional level in order to reduce the excess production of sub – viral 
particles and, by relieving HBsAg – mediated immunosuppression, aimed at 
restoring antiviral immunity.  
 
HBV secretory pathways. α-Glucosidase inhibitors (Block et al., 1994); 
(Durantel et al., 2007) and triazol – o – pyrimidine derivatives (Yu et al., 2011) 
both inhibit HBV secretion. However, retention of HBV envelope proteins raises 
concerns about the activation of stress signals with oncogenic potential. More 
recently, the benzimidazole compound BM601 has been shown to inhibit 
selectively the intracellular relocalization of the HBV surface proteins to the 
Golgi leading to decreased HBsAg and HBV release without inducing ER stress 
or affecting cellular proteins and HBeAg secretion (Xu et al., 2014). Nucleic Acid 
Polymers (NAPs), previously referred to as amphipathic DNA polymers (APs), 
are sequence – independent phosphorothioated oligonucleotides (PS – ONs) that 
display a broad spectrum of antiviral activity against several enveloped viruses, 
including HBV. Since NAPs activity is not sequence dependent they can be 
engineered to retain their antiviral potency without the pro – inflammatory 
activity and the off target effects common to other oligonucleotide – based drugs. 
AT130 
A 
HAP12 
B 
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REP9-AC (REP 2055), a 40-nucleotide polycytidine amphipathic DNA polymer, 
inhibits DHBV infection (Noordeen et al., 2013) and HBsAg release from 
infected hepatocytes, and prevents the establishment of DHBV infection in vivo 
(Petersen et al., 2016). Recent in vivo data obtained in the DHBV model have 
validated new NAPs (REP 2165) with antiviral activity comparable to REP 2139 
but significantly lower liver accumulation (Petersen et al., 2016) and showed that 
an interferon free regimen of REP-2139 with TDF or ETV improved antiviral 
outcomes and allows the shortening of antiviral regimens in patients with chronic 
HBV infection (Petersen et al., 2016). Larger controlled studies and a 
comprehensive evaluation of HBV and HDV virology in the liver of NAPs 
responder patients are needed together with immunological studies to evaluate the 
occurrence and the extent of immune restoration following NAPs induced HBsAg 
clearance (Petersen et al., 2016). 
RNA interference (RNAi). RNA interference describes the conserved biological 
pathway for sequence – specific mRNA cleavage and gene silencing (Randall and 
Rice, 2004); (Bernstein et al., 2001); (Hammond et al., 2000). HBV is an 
attractive therapeutic target for RNAi strategies the overlapping reading frame 
means that multiple transcripts can be targeted with a single siRNA sequence. The 
first wave of RNAi candidates were being developed to knock down production of 
HBV proteins with the intention of restoring the anti – HBV immune response. 
The primary focus is HBsAg, although HBeAg, HBcAg and HBxAg are all of 
interest. There have been a number of challenges: siRNA are not bioavailable and 
require parenteral (SC/IV) delivery, carrier molecules are necessary to prevent 
nuclease degradation and for hepatocyte targeting, but must have a good safety 
profile, and allergic reactions have been reported. Careful sequence design is 
necessary to limit the risk of off – target gene silencing. Multiple siRNA may be 
necessary to prevent the selection of resistant HBV mRNAs. Three candidates 
have entered clinical development. ARC-520 is composed of two cholesterol – 
conjugated siRNA duplexes directed against 2 different HBV sequences in the 
DR1-DR2 region that are highly conserved among all HBV genotypes (Wooddell 
et al., 2013). An ongoing phase 2a single – dose – escalation study in humans has 
demonstrated reduction in serum HBsAg with mean nadir -51% (range -46 to -59) 
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with a mean change on day 85 of -22% (range -7 to -40). Reductions in HBeAg 
and HBV core – related  antigen were also observed.  ALN – HBV is a second 
siRNA formulation for the treatment of HBV infection that employs a lipid 
nanoparticle (LNP) formulation for drug delivery to the liver. This agent can be 
delivered subcutaneously. The target sequences have been designed to knock 
down all HBV transcripts (0.7 kb region overlapping all 4 transcripts and 1.4 kb 
region overlapping across 3 transcripts [S, pol, pregenomic RNA]). ALN – HBV 
has entered phase 1 development. TKM – HBV is a third RNAi therapeutic. TKM 
– HBV must be delivered intravenously, and also employs an LNP formulation 
for hepatocyte delivery (Petersen et al., 2016). TKM – HBV simultaneously 
targets three sites on the HBV genome, including integrated S-ORF. In a 
humanized mouse model of HBV, TKM – HBV was associated with reductions in 
HBsAg, HBeAg, HBV DNA and cccDNA. A phase 1 program has been initiated 
in 2015 (Petersen et al., 2016).  
The early RNAi experience is also providing new insights into HBV biology and 
the potential utility of HBsAg as a treatment end – point. Emerging data from the 
Arrowhead chimp studies highlight the relative importance of integrated HBV 
DNA relative to cccDNA for HBsAg production. The data suggest that in 
HBeAg-negative animals a significant fraction of circulating HBsAg was derived 
from integrated HBV DNA producing Pre-S/S transcripts that had lost the ARC-
520 target sites, rather than from cccDNA. The implication is that cccDNA could 
potentially be eradicated and yet an individual remain HBsAg – positive, due to 
HBsAg production from integrated HBV DNA. This is an important issue for the 
field, both for therapeutic development, as well as prognostication, particularly for 
individuals in the immune control phase of CHB. ARC-521, a 2nd generation 
RNAi agent, has been designed to knock down HBsAg derived from both 
integrated HBV DNA as well as cccDNA (Petersen et al., 2016).  
Cyclophilin inhibitors  
Cyclophilins are cytoplasmic proteins involved in the life cycle of a wide range of 
viruses including HCV and human immunodeficiency virus. Alisporivir is a 
cyclophilin A inhibitor that was developed for the treatment of HCV. Recent 
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preclinical data suggest that alisporivir also inhibits HBV DNA replication as well 
as HBsAg production and release (Phillips et al., 2015). A clinical program is 
planned. OCB-030 (formerly NVP018) is a second generation cyclophilin 
inhibitor. Preclinical data suggest that OCB-030 has dual anti – HBV activity 
including direct inhibition of HBV replication, as well as immune modulation via 
interferon regulatory factors (IRFs), including potent inhibition of an interaction 
between cyclophilin A and IRF9 (Petersen et al., 2016).  
Immunomodulation  
Over the past decade, studies of the immunopathogenesis of HBV infection have 
identified a number of potential novel approaches.  
Innate immune ligands  
Toll – like Receptor (TLR) ligands. Toll – like receptors are pattern recognition 
receptors that play a key role in the recognition of foreign pathogens, both 
bacteria and viruses, as part of the innate immune response (Thompson and 
Locarnini, 2007). TLR expression and signalling is involved in the pathogenesis 
of HBV (Broering et al., 2014); (Jiang et al., 2014); (Wu et al., 2010); (Wu et al., 
2007); (Thompson et al., 2009); TLR3, 7/8 and TLR9 represent a TLR subfamily 
that recognize endosomal viral nucleic acids (dsRNA, ssRNA and CpG motifs 
respectively), and induce a type-1 interferon response. Therapeutic manipulation 
of this pathway is possible and a TLR7 agonist is in clinical development 
(Lanford et al., 2013); (Gane et al., 2015). 
RIG-I ligands. Retinoic acid-inducible gene (RIG-I)-like RNA helicases (RLHs) 
are a second class of innate pattern recognition receptors. RLHs recognize dsRNA 
in the cytoplasm. RIG-I has been recently shown to have dual antiviral effect 
against HBV (Sato et al., 2015). RIG-I recognizes the 5′-ε region of HBV pgRNA 
leading to induction of a predominantly type III interferon response. RIG-I also 
counteracts the interaction of the HBV polymerase with pgRNA to directly 
suppress viral replication. SB-9200 is an oral dinucleotide prodrug; the active SB 
9000 isomer products bind to RIG-I and NOD2 to stimulate an interferon 
response. SB-9200 has activity against both HCV and HBV in preclinical models 
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and was recently used sequentially in combination with ETV in the woodchuck 
model (Petersen et al., 2016).  
Check – point inhibitors  
Chronic hepatitis B infection is associated with an “exhausted” HBV – specific 
CD8+ T cell phenotype, characterized by high levels of expression of inhibitory 
molecules including programmed cell death protein 1 (PD-1), cytotoxic T 
lymphocyte antigen 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), T cell 
membrane 3 (Tim-3) and CD244 (2B4) (Chen and Flies, 2013); (Raziorrouh et 
al., 2010); (Blackburn et al., 2009). Collectively these molecules are termed 
‘checkpoints’. Checkpoint inhibitors, which block these inhibitory pathways, have 
been shown in experimental models to rescue virus specific CD8+ T cells by 
improving proliferation, cytotoxicity and cytokine production (Fisicaro et al., 
2010); (Nebbia et al., 2012); (Schurich et al., 2011); (Peppa et al., 2010). 
Nivolumab (BMS-936558) and pembrolizumab (MK-3475) are both anti – PD-1 
monoclonal antibodies that have progressed through phase 3 development for the 
treatment in oncology. Grade 3 – 4 adverse events have been seen in 
approximately 15% of patients treated with nivolumab in oncology patients, A 
phase 1 study of nivolumab for the treatment of advanced hepatocellular 
carcinoma that included patients with CHB has been presented in abstract form 
(Petersen et al., 2016). Phase 1 studies of anti – PD-1 therapies for the treatment 
of CHB have not yet commenced, but are likely.  
cIAP inhibitors  
Cellular inhibitor of apoptosis proteins (cIAPs) have recently been shown to 
attenuate TNF signaling during HBV infection and restrict the death of infected 
hepatocytes, promoting viral persistence. Antagonizing the function of cIAPs may 
therefore promote the clearance of HBV infection. Birinipant is already in clinical 
development for the treatment of advanced malignancy. A phase 1 study of 
birinapant for the treatment of HBV was initiated in 2015 (Petersen et al., 2016). 
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VACCINATION  
Prophylactic vaccination 
In view of the still unsatisfactory therapy of HBV infections prevention has 
highest priority. Besides obeying strict hygiene with all invasive procedures and a 
considerate life style, vaccination is the most important way to prevent hepatitis B 
diseases. In 1975 that Blumberg’s concept of using purified 20 nm HBsAg 
particles from carrier plasma as HB vaccine was valid and could protect against 
an intravenous challenge with 3000 chimpanzee – infectious doses (Purcell and 
Gerin, 1975). Philippe Maupas and Alain Goudeau went one step further and used 
purified formalin – treated purified HBsAg as vaccine. In 1976 they reported good 
protection rates particularly in the staff of hemodialysis wards (Maupas et al., 
1976). With the cloning of the HBV genome and the identification of the HBs 
gene in 1979 a new era of  vaccine production was opened. It appeared logical to 
use the gene encoding the major HBs protein for production of the “recombinant” 
vaccine, i.e. using recombination of the gene with the DNA of expression vectors. 
The vaccine was generated thanks to yeast cell strains which expressed the major 
HBs protein in very large amounts at low cost (Harford et al., 1983). Thus, in 
1986 yeast – derived HBsAg became the standard vaccine against HBV. Although 
these historical studies of therapeutic vaccination for HBV using traditional HBV 
protein vaccines have been disappointing, this approach is still being pursued with 
new vaccine candidates. ABX203 is a therapeutic vaccine composed of 2 
recombinant proteins, HBsAg and HBcAg. A phase 2B/3 study of the efficacy of 
ABX203 for maintaining persistent HBV DNA suppression in HBeAg – negative 
patients after cessation of NA therapy is currently enrolling. Novel vaccine 
approaches currently in clinical development include GS-4774 (Gaggar et al., 
2014), TG1050 (Martin et al., 2015), and INO-1800 (Obeng-Adjei et al., 2013). 
GS-4774 is a tarmogen vaccine made from genetically modified yeast expressing 
HBV core, X, and surface proteins. GS-4774 elicited HBV specific T cell immune 
responses in a phase 1 study (Gaggar et al., 2014). The results of a phase 2 dose-
finding study evaluating GS-4774 for 24 weeks in patients virally suppressed by 
long – term NA have recently been presented. The primary endpoint was 
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reduction in HBsAg level. Modest reductions in HBsAg were observed; no 
patients lost HBsAg (Petersen et al., 2016). GS-4774 appeared to be safe and well 
tolerated. A second phase 2 study evaluating the efficacy of combination therapy 
of GS-4774 plus tenofovir for treatment naïve patients is currently enrolling. 
TG1050 is an adenovirus – based immunotherapy encoding a unique large fusion 
protein composed of a truncated HBcAg domain, a modified HBV Polymerase 
domain and two HBsAg domains. In a murine model of HBV TG1050 induced a 
robust cross – reactive T cell response leading to reduction in HBV DNA and 
HBsAg levels (Martin et al., 2015). A phase 1 program started in late 2015. INO-
1800 is a DNA vaccine encoding HBsAg and HBcAg that generated robust 
cytotoxic and antibody responses in mice and Rhesus macaques. A phase 1 open-
label dose escalation study of  INO-1800 in combination with INO-9112 (DNA 
plasmid encoding human interleukin 12) delivered by electroporation in HBeAg – 
positive, HBV DNA – negative patients taking entecavir or tenofovir is planned. 
As a proof of concept study, in a preclinical transgenic mouse model, it was 
shown that reducing first viral antigens with an adeno-associated virus targeting 
HBV transcripts via RNAi, followed by a boost vaccination with an protein 
prime/modified vaccinia virus Ankara (MVA) virus was sufficient to induce some 
HBV specific T cell responses (Petersen et al., 2016). Finally, preclinical data 
support the concept of T – cell  therapies. Engineering HBV – specific T cells 
through transfer of HBV – specific T cell receptor or HBV – specific chimeric 
antigen receptors represent promising alternative strategies to construct an HBV-
specific T – cell  immunity in many CHB patients (Krebs et al., 2013); (Gehring 
et al., 2011). 
HBV CORE PROTEIN BINDING TO HOST GENE 
PROMOTERS  
HBV targets host genes that are involved in cell survival, and while this facilitates 
escape from immune surveillance and clearance, it also favors malignant 
transformation (Brechot, 2004). One of the possible mechanisms that contributes 
to malignant transformation involves HBV – encoded transactivating factors, 
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which influence particular intracellular signal transduction pathways by altering 
the host gene expression profile in hepatocytes (Lee and Lee, 2007). Several HBV 
protein products have been characterized as modulators of cellular growth, repair, 
and death, all of which are involved in oncogenesis (Murakami, 1999). Studies 
have shown that HBx can transactivate the expression of all HBV proteins, 
including HBc, which acts as the core antigen that stimulates the human immune 
response. The 21 – 22 kDa HBc protein has been detected in both the nuclear and 
cytoplasmic compartments of hepatocytes infected by HBV (Petit and Pillot, 
1985). Subsequent studies have revealed pleiotropic functions of HBc that affect 
host processes, including the malignant transformation of chronically infected 
liver cells (Guo et al., 2012). Moreover, this newly – recognized dual character of 
HBc as a novel regulator of the HBV life cycle and of hepatocellular 
carcinogenesis has been hypothesized to involve HBx, possibly through an 
inhibitory feedback mechanism (Kim et al., 2003). HBc was shown to repress the 
expression of the human tumorigenesis – associated genes, interferon (IFN) – β 
and p53 (Kwon and Rho, 2003); the latter of which is also modulated by HBx, via 
binding to the encoded protein and suppressing its activity (Elmore et al., 1997). 
Additionally, recent studies have suggested that HBV down – regulates the human 
IFN inducible MxA promoter through direct interaction of precore/core proteins 
(Fernandez et al., 2003), and have shown that HBc inhibits apoptosis induced by 
the tumor necrosis factor family member, TRAIL, in hepatocytes by blocking 
gene expression of the pathway-related death receptor (Guo et al., 2012). 
Collectively, these studies indicate that HBc may interact with the human genome 
to modulate normal functions of liver cells infected HBV (Guo et al., 2012). 
Although HBc has been sufficiently demonstrated by many studies to functionally 
bind to both virus- and host- derived RNA and DNA, the way in which HBc 
interacts with the human genome to modulate normal hepatocyte function in HBV 
infection remains unknown. Based on the findings of in vivo studies that showed 
core particles binding specifically to the HBV pregenome and genome, we 
hypothesized that HBc may also bind specifically to certain human gene 
promoters, either through its C – terminal functional domain or its N – terminal  
assembling domain (Guo et al., 2012). A recently developed high-throughput 
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strategy to perform targeted or genome – wide studies of transcription binding 
factors is the chromatin immunoprecipitation (ChIP) – coupled DNA microarray 
analysis. Known as ChIP – on – chip, this technique couples immunoprecipitation 
of chromatin – bound transcription factors with the identification of bound DNA 
sequences through hybridization on DNA microarrays (Guo et al., 2012). In a 
recent study Guo Y. et al. used a combination of ChIP and location analysis with 
genome – wide  tiling arrays to generate a human genome – wide  binding profile 
of HBc. The human genes whose promoters were bound by HBc and had 
functions related to tumorigenesis were selected for verification by quantitative 
PCR (qPCR) and functional analysis by gene expression assays. Identification of 
the human gene targets of the HBV – encoded  HBc protein provides further 
insights into HBV pathogenesis and potential new targets of molecular 
therapeutics against HBV – associated hepatocellular carcinogenesis (Guo et al., 
2012). We performed ChIP-on-chip analysis with the NimbleGen HG18 RefSeq 
Promoter Microarray consisting of 18028 of the best defined human transcript – 
associated promoters. Raw microarray data were extracted as pair files by the 
NimbleScan software. They performed median – centering, quantile 
normalization, and linear smoothing by using the Bioconductor packages, Ringo, 
Limma, and MEDME. The gene ontology (GO) and pathway analysis of 
promoter-related genes were carried out online (http:// www.geneontology.org). 
Gene pathway analysis was conducted with the Kyoto Encyclopedia of Genes and 
Gen- omes (KEGG) collection of online databases dealing with genomes, 
enzymatic pathways, and biological chemicals (Guo et al., 2012). Hepatocytes 
infected with HBV and expressing HBV core protein were isolated from CHB 
patients, immunoprecipitated with HBc antibody, and investigated to determine 
the genome – wide profile of bound host gene promoters. In total, 3100 HBc – 
immunoprecipitated host promoter regions were found to be enriched by at least 2 
– fold in HBc – infected  tissues compared to the blank controls. They showed 
that the HBV core protein might bind to a broad spectrum of human gene 
promoters, especially those featuring high CpG density. The GO annotations for 
biological processes were found for 1933 of the genes related to the 
immunoprecipitated promoters, and annotations for molecular functions were 
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found for 2022. The biological processes represented within this dataset of 
putative HBc targets included: metabolic process 1404; primary metabolic process 
1286; cellular metabolic process 1248; and biological regulation 1206 Figure 16. 
In addition, a remarkable amount of genes were found to be associated with 
dsRNA fragmentation, and intermediate filament cytoskeleton organization Figure 
17. These results suggested that HBV core protein can bind to host gene 
promoters, especially those involved in tumor pathogenesis (Guo et al., 2012). 
 
 
 
Figure 16: Count proportion pie of the GO analysis of Biological Process. The chart 
shows the top ten counts of the significant enrichment terms of designed gene involving 
Biological Process (Guo et al., 2012). 
 
 
Figure 17: The bar plot of the GO analysis of Biological Process. The bar plot shows 
the top ten fold enrichment value of the significant enrichment terms of designed gene 
involving Biological Process (Guo et al., 2012). 
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AIM 
Infection with hepatitis B virus continues to be a major health problem with about 
400 million people chronically infected worldwide who are at high risk of 
developing liver cirrhosis and hepatocellular carcinoma (HCC) (Guerrieri et al., 
2013). HCC is one of the most frequent solid tumors worldwide and represents the 
third cause of mortality among deaths from cancer (Zucman-Rossi and Laurent-
Puig, 2007) and recent estimates attribute to HBV >50% of HCC cases 
worldwide. Currently available treatments in patients with chronic HBV hepatitis, 
based upon direct nucleos(t)ides analogs targeting the viral RT/Polimerase, 
suppress viral replication and halt disease progression in >98% of the patients. 
However, these treatments as well as Interferon based regimens, cannot 
completely eliminate the infection and the rate of “functional cure” (i.e. viral 
control without ongoing treatment) is as low as 10 – 15% (Vlachogiannakos and 
Papatheodoridis, 2013). There are two strategies to defeat HBV: eradication that 
means driving the virus to extinction from the earth (vaccination is the tool); cure 
that means eliminating the virus from the infected host (an effective treatment 
would be the tool). The barrier to cure chronic hepatitis B is the cccDNA. HBV 
cccDNA is the obligatory replicative intermediate  responsible for persistent 
HBV infection and is the template for the transcription of all viral mRNAs, 
including the pregenomic RNA (pgRNA) which is reverse transcribed to produce 
the first HBV DNA strand. The accumulation and the maintenance of the cccDNA 
pool is ensured in infected hepatocytes by newly synthesized nucleocapsids which 
are not enveloped and secreted into the blood, but are transported into the nucleus. 
In quiescent cells the cccDNA is very stable and can persist throughout the life 
span of the hepatocytes without affecting its viability. Very low levels of cccDNA 
can persist indefinitely, possibly explaining lifelong immune responses to HBV 
despite clinical resolution of HBV infection. Many strategies can be applied to 
overcome this barrier: improve NAs potency, broaden viral targets (viral entry, 
nucleocapsid or virion assembly...), deplete or silence cccDNA. 
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HBV is a DNA virus organized into nucleosomal structures. HBV produces 
covalently closed double – stranded DNA (cccDNA) that is found in the nuclei of 
infected cells as a viral minichromosome (Levrero et al., 2009). HBV encoded 
proteins HBx and HBc both bind the cccDNA early after infection (Belloni et al., 
2009); (Bock et al., 2001).  HBx is required for the inactivation of the HBV 
cellular restriction factor smc5/6 (decorsiere) and to establish and maintain 
cccDNA transcription (Levrero et al., 2009); (Riviere et al., 2015). HBc binding 
to the cccDNA in thought to contribute to cccDNA chromatinization and 
nucleosome spacing (Bock et al., 2001) whereas its impact on cccDNA 
transcription is still debated. 
Increasing evidence indicate that HBV proteins regulating viral minichromosomes 
also interact with the cellular chromatin and chromatin modifying enzymes to 
target cellular genes expression through epigenetic modifications (Cougot et al., 
2007); (Cougot et al., 2012). A ChIP – Seq genome wide analysis of HBx 
chromatin recruitment in HBV replicating cells has defined a broad repertoire 
cellular genes (~4.000) of and ncRNAs (75 miRNAs and 34 lncRNAs) potentially 
regulated by HBx with an enrichment in genes/ncRNAs involved in cell 
metabolism, chromatin dynamics and cancer but also in genes/ncRNAs that 
modulate HBV replication. HBc has also been shown to bind to cellular chromatin  
(~1000 genes) (Guo et al., 2012) and to the promoters of a subset of cellular genes 
involved in inflammatory responses and innate immunity. 
Core protein (Cp) represents an attractive new therapeutic specific target for HBV 
chronic infection. Cp is essential for HBV genome packaging, reverse 
transcription, intracellular trafficking and the reimport of encapsidated HBV 
genomes into the nucleus, but due to its nuclear functions drugs targeting the Cp 
may also impact on cccDNA transcriptional activity and host genes 
reprogramming with a great potential for enhanced antiviral activity. The 
elucidation of the HBc crystal structure and the clarification of core dimers 
assembly process has led to the development of several compounds that target Cp 
and capsid assembly inhibit HBV replication therapeutic potential (Zlotnick et al., 
2015). We focused on two different classes of Cp assembly modulators. 
Heteroaryldihydropyrimidines (HAPs) act as allosteric effectors to increase the 
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kinetics of assembly, strengthen dimer – dimer association and prevent the proper 
formation of viral capsids with the formation of aberrant core particles at high 
concentrations (Stray et al., 2005). The phenyl – propenamide derivatives AT – 
61 and AT – 130 increase capsid assembly reaction rate, interfere with HBV RNA 
packaging and to the formation of apparently normal empty capsids. Interestingly, 
compounds belonging to the HAP chemical class have moved into clinical trials.  
 
In this study I will focus on the impact of two classes of capsid inhibitors HAP – 
12 and AT – 130 on the formation, accumulation and transcription of cccDNA as 
part of their anti – HBV activity in HBV replicating cells, I will evaluate the 
activity of HAP – 12 on HBV replication in new, more relevant HBV infection 
models: NTCP – HepG2 (Na+/taurocholate co – transporting polypeptide) 
infection system and primary human hepatocytes (PHH), and I will investigate the 
impact of HAP – 12 treatment on HBV Cp recruitment on the cccDNA and to 
expand these observation on the regulation of cellular genes targeted by Cp. 
All relevant virological parameters will be evaluat: capsid – associated HBV – 
DNA, cccDNA levels (TaqMAN real – time PCR) and pgRNA levels 
(quantitative real – time PCR). Nuclear cccDNA will be visualiz by DNA 
Fluorescence In Situ Hybridization (FISH) using HBV specific probes 
encompassing the whole HBV genome. Anti-Hbc, anti-HBx and anti-AcH4 
Chromatin Immuno Precipitations (ChIPs) and cccDNA – ChIP experiments will 
be performe in TET-released HepAD38 cells and in mock and HBV-infected 
NTCP – HepG2 cells and PHHs and analyzed by TaqMan real – time PCR using 
cccDNA and gene specific primers.     
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MATERIALS AND METHODS 
MATERIALS  
CHEMICALS AND REAGENTS 
Dimethyl sulfoxide (DMSO)  
 
Sigma-Aldrich  
 
DNase I 
 
Sigma-Aldrich  
 
Dulbecco's Modified Eagle Medium (DMEM)   
 
Life technologies  
 
ECL western blotting detection Reagents  
 
GE Healthcare  
 
EcoRI  
 
New England biolabs  
 
Ethylenediaminetetraacetic acid (EDTA)  
 
Sigma-Aldrich  
 
Ethanol 
 
Sigma-Aldrich  
 
Formaldehyde 
 
Sigma-Aldrich  
 
G-418  
 
Life technologies  
 
Glycogen 
 
Roche  
 
Hydrocortinson 
 
Sigma-Aldrich  
 
Insulin 
 
Sigma-Aldrich  
 
76 
 
Isopropanol  
 
Sigma-Aldrich  
 
Maxima H minus first strand cDNA synthesis kit   
 
Thermo scientific  
 
MES SDS running buffer  
 
Life technologies  
 
MgCl2  
 
 
milkpowder 
 
Biorad  
 
NaCl 
 
Sigma-Aldrich  
 
NP-40  
 
Sigma-Aldrich  
 
NuPage Bis-Tris Gel  
 
Life technologies  
 
PBS 1X  
 
Life technologies  
 
Penicilin-streptomycin  
 
Sigma-Aldrich  
 
Piperazine N,N bis zethone sulfonic acid (PIPES)  
 
Sigma-Aldrich  
 
Plasmid-Safe ATP dep. DNase  
 
Epicentre  
 
Polyethylenglycol (PEG) 8000  
 
Sigma-Aldrich  
 
Proteinase!inhibitor (PIC)  
 
Sigma-Aldrich  
 
Proteinase K   
 
Sigma-Aldrich  
 
PvuI  
 
New England biolabs  
 
RQ1 RNase-Free DNase  Promega 
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RQ1 RNase Free DNase stop solution  
 
Promega 
 
Sodium dodecyl sulphate (SDS)  
 
Sigma-Aldrich  
 
TransIT-LT1  transfection reagent  
 
Mirus  
 
Triton X-100  
 
Sigma-Aldrich  
 
Trizol  
 
Life technologies  
 
FISH kit  Life technologies  
 
MTT Sigma-Aldrich 
 
CELLS 
 
Name Description 
HepG2 These human hepatoma cells are derived from a 15 years old HCC 
patient from Argentina (Knowles et al., 1980); (Aden et al., 1979).  
 
HepAD38 This human hepatoma cell line is derived from HepG2 cells which 
are stably transfected with a plasmid containing the HBV pgRNA 
under the control of a tetracycline-inducible promoter (Ladner et al., 
1997).  
 
NTCP-HepG2 Stable clone expressing high levels of the HBV entry receptor 
Na+/taurocholate co – transporting polypeptide (NTCP), that allow 
HBV infection in vitro (Ni et al., 2014).  
PHHs Primary human hepatocytes from multiple donors infeted with HBV 
inocula purified from the cell supernatants of HepAD38 stable cell 
lines. 
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CELL CULTURE MEDIA  
Cells Medium 
HepG2 DMEM (Gibco); 10%FBS (Gibco); 2mM L-
Glutamine; 50U/ml Penicillin; 50µg/ml Streptomycin  
 
HepAD38 Culture medium: DMEM/F012; 10% FCS (not heat 
inactivated); 50U/ml Penicillin; 50µg/ml 
Streptomycin; 400µg/ml G418, 50µM Hydrocortisone-
Hemisuccinate; 5µg/ml Insulin; 0,3µg/ml Tetracycline 
 
Virus production medium: culture medium without 
tetracycline 
  
 
NTCP – HepG2 Culture medium: see HepG2 plus 5µg/ml 
Puromycin 
 
Infection medium: culture medium plus 2,5% DMSO 
PHHs Bought them on Life Technologies website; growth 
medium as indicated in their protocol 
 
Infection medium: culture medium plus 2,5% DMSO  
 
ANTIBODIES 
Anti-HBc U.S. biological, cat no. H19015-15  
Anti-HBx Thermo Scientific, cat no. MA1-081 
Anti-H4 Abcam, cat no. ab10158 
Anti-AcH3 Upstate, cat no. 07-352 
Anti-AcH4 Millipore, cat no. 06-866  
Anti-ACTIN Santa Cruz Biotechnology, cat. no. sc1616   
Anti-LaminB Santa Cruz Biotechnology, cat. no. sc6216   
Donkey anti-goat IgG-HRP Santa Cruz Biotechnology, cat. no. sc2020   
Donkey anti-rabbit IgG-HRP Santa Cruz Biotechnology, cat. no. sc2316   
Donkey anti-mouse IgG-HRP Santa Cruz Biotechnology, cat. no. sc2005   
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PRIMERS AND PROBES  
cccDNA 
Primers: FOR – CTCCCCGTCTGTGCCTTC    
REV – GCCCCAAAGCCACCCAAG 
 
Probes: GTTCACGGTGGTCTCCATGCAACGT-FL                                                                         
R640-AGGTGAAGCGAAGTGCACACGGACC  
 
HBV DNA 
Primers: FOR – CTCGTGGTGGACTTCTCTC 
REV – CAGCAGGATGAAGAGGAA 
 
Probes: CACTCACCAACCTCCTGTCCTCCAA – FL  
R640 – TGTCCTGGTTATCGCTGGATGTGTCT 
 
β-GLOBIN 
Primers: FOR – ACACAACTGTGTTCACTAGC 
REV – CAACTTCATCCACGTTCACC 
 
Probes: CAAACAGACACCATGGTGCACCTGACTCCTGAGGA – FL  
Red640 – AAGTCTGCCGTTACTGCCCTGTGGGGCAA  
 
pgRNA 
Primers: FOR – GCCTTAGAGTCTCCTGAGCA 
REV – GAGGGAGTTCTTCTTCTAGG  
 
Probes: AGTGTGGATTCGCACTCCTCCAGC – FL 
Red640 – ATAGACCACCAAATGCCCCTATCTTATCAAC 
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ACTIN-B 
Primers: FOR – GCACTCTTCCAGCCTTCCT  
REV – AGGTCTTTGCGGATGTCCAC   
 
Promoter – EZH2  
Primers: FOR – ACATAATCAAACAGGGCCCGGG 
REV – TTGGTCAGGCTGGTCTCGAACTCC  
 
Promoter – SRC  
Primers: FOR – TCCTGTCGTGACCGTCTCCTCTCT 
REV – CTTGATCTGCCTGGCCTGATGG 
 
Promoter – E2F1 
Primers: FOR – CGTTGGCTGTTGGAGATT  
REV – AGAGCCCAAGCTGAAGA  
 
Promoter – IL29 
Primers: FOR – GCCCAGGGAGTTCTAAGGAT  
REV – CTGATGAGGGAACAGGTGTG  
 
Promoter – GAPDH  
Primers: FOR – CTTCTCCCCATTCCGTCTTC  
REV – CCCCAGCTACAGAAAGGTCA  
 
Promoter – TP53 
Primers: FOR – GAGTGCAGTGGCACGATTT  
REV – GAATCGCTTTCAGCTCAGGA  
 
Promoter – IL6 
Primers: FOR – CAGAGGAGAACCTGCACTATTC  
REV – CAGTTTCAGTGCAGGGTAGAA   
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METHODS 
CULTIVATION OF EUCARYOTIC CELLS  
The cultivation of eukaryotic cells was done - if not other stated otherwise at 37° 
C in the presence of 5% CO2 and a humidity of 95%. Prior to use cells were 
thawed and cultivated with the respective medium in a flask or cell culture dish. 
During cultivation, the cells were split twice a week. Therefore, the cells were 
washed with 1x PBS and incubated with 1x trypsin to get detached from the 
surface. After 50 10 min of incubation, the cells were resuspended in new culture 
medium by pipetting up and down to obtain a single cell suspension. Cells were 
split depending on cell type and growth conditions. 
VIRUS PRODUCTION 
HepAD38 cells were cultivated in HepAD38 culture medium (supplemented with 
tetracycline). After two weeks, the culture medium was replaced by virus 
production medium (without tetracycline) to induce the production of HBV.  
HBV VIRUS CONCENTRATION  
The supernatants from induced HepAD38 cells were collected from day 9 to 14 
and centrifugated at 4000 rpm for 10 min. The supernatants were mixed 
thoroughly with 40% PEG8000 to a concentration of 6% PEG8000 and incubated 
overnight at 4° C. The samples were centrifuged for 1h at 10000rpm, 4° C and the 
pellet was resuspended in 1/100 of the sample volume in PBS with 10% FCS. The 
samples were thoroughly vortexed overnight at 4° C and centrifuged at 8000 rpm, 
5min at 4° C. The virus – containing supernatants were collected and stored at      
-80° C in aliquots for further use.  
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HBV INFECTION OF NTCP – HepG2 AND PHH CELLS  
For HBV infection of NTCP – HepG2 and PHH cells, the cells were seeded in a 
density of 2 x 105 cells/well in a 6-well  plate. 1 day after seeding the medium was 
exchanged and differentiation medium (supplemented with 2,5% DMSO) was 
added. Two days after seeding the cells were inoculated with 1,5 x 108 of the PEG 
– precipitated HBV virus mixed with 40% PEG 8000 and infection medium to a 
total volume of 800 µl. The medium of the cells was removed and the mixture was 
added to the cells. After at least 16 h of incubation, the cells were washed 3 times 
with 1x PBS and infection medium was! added. The medium was changed every 
second or third day, depending on the experiment. To verify the specificity of the 
infections, mock cells were inoculated with infection medium with 40% PEG 
8000.  
DNA AND RNA QUNATIFICATION  
The nucleic acids concentration was measured with a UV-Vis Spectrophotometer 
at 260 nm and 280 nm against ddH2O. An absorbance of 1 at 260 nm corresponds 
to a concentration of 50 µg/ml dsDNA and to a concentration of 40 µg/ml RNA. 
The quality of the DNA was examined by measurement of the absorbance at 280 
nm (absorbance maximum of proteins) and therefore samples were considered to 
be  pure when the ratio of OD 260/OD 280nm was between 1,8 for DNA and 2 for 
RNA. 
TRANSIENT TRANFECTION OF FULL – LENGTH HBV DNA 
GENOMES 
Monomeric linear full length wild – type (WT) genomes were released from the 
pCR.HBV.A.EcoRI using EcoRI – PvuI. Linear HBV monomers were transfected 
into HepG2 human hepatoma cells using the Mirus Bio trans IT-LT1. Briefly, 
HepG2 cells were seeded at a density of 2-3 millions of cells in 100 mm diameter 
Petri dishes and transfected 24 hours later with 1 mg to 2 mg of digested HBV 
DNA. Unless specified otherwise, culture medium was changed 1 day after 
transfection and cells were harvested after 48 hours. All transfection included 0,5 
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mg of green fluorescence protein expression vector (GFP) to assess transfection 
efficiency (HepG2 cells range 28-32%).  
CELL CULTURES AND TREATMENTS 
Four cellular models of HBV infection/replication: 
HepG2 hepatoma cells were trasfected with a linear full – lenght genotype A 
HBV DNA (Gunther et al., 1995), than were treated with the anticapsid HAP – 12 
used at a final concentration 1 µM concentration and added directly to the culture 
medium, 30 min after transfection. The treatment was repeated daily. The cells 
were harvested 96 hours post treatment. Untreated cells were exposed to the same 
DMSO final concentration. 
HepAD38 cells, a stable clones derived from the hepatocellular cell line HepG2, 
carry a complete integrated HBV genome under the control of a tetracycline – off 
inducible promoter. Upon tetracycline removal, the viral pgRNA and mRNAs are 
transcribed from the integrated HBV DNA leading to the accumulation of subviral 
particles in the cytoplasm and cccDNA in the nucleus and secretion HBV virions 
in the cell supernatant  (Ladner et al., 1997). 
TET – off system: cells were induced and treated with core – inhibitors HAP – 12 
and AT – 130 respectively 1 and 5 µM for 10 days, from the moment of the 
beginning of viral replication. Untreated cells were exposed to the respectively 
same DMSO final concentration. 
TET – on system: after a first 6 days period in which confluent cells were allowed 
to replicate HBV from the integrated genome (TET – off) leading to the 
accumulation of a cccDNA pool into the nucleus, capsids  containing pgRNA and 
mature viral particles into the cytoplasm, 0.3 µg/ml tetracycline was added daily 
to culture medium for 7 days to inhibit integrated HBV DNA replication and to 
allow cccDNA transcription. TET – on HapAD38 were treated for six days 
starting 1 day later the introduction of Tet in the medium with HAP – 12 at final 
concentration of 1 µM. Untreated cells were exposed to the same DMSO final 
concentration.  
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NTCP – HepG2 cells were infected as described and manteined in differentiation 
medium. HAP – 12 1 µM was added daily for 10 days 1 day after infection, or 
daily for 6 days after a period of 10 days to allow the accumulation of viral 
intermediates. Untreated cells were exposed to the same DMSO final 
concentration.  
PHH cells were infected as described and manteined in differentiation medium. 
HAP – 12 1 µM was added daily for 6 days after a period of 10 days to allow the 
accumulation of viral intermediates. Untreated cells were exposed to the same 
DMSO final concentration. 
PURIFICATION AND QUANTIFICATION OF CORE PARTICLES 
ASSOCIATED WITH HBV DNA FROM HBV – REPLICATING 
CELLS  
To purify HBV DNA from intracellular core particles, the cells were washed once 
with ice-cold PBS and lysed in 50 mmol Tris-HCl, pH 7.4, 1 mmol EDTA, and 
1% NP-40 (lysis buffer A). Nuclei were pelleted by  centrifugation for 1 minute at 
10.000 g. The supernatant was adjusted to 100 mmol MgCl2 and treated with 100 
mg/ml of DNase I for 60 minutes at 37° C. The reaction was stopped by adding 
EDTA to a final  concentration of 25 mmol. Protein was digested with 0.5 mg/ml 
proteinase K and 1% SDS over night at  56° C. Nucleic acids were purified by 
phenolchloroform (1:1) extraction and isopropanol precipitation adding 0,1 M 
NaCl. HBV DNA was quantified by real – time PCR in a Light Cycler instrument 
(Roche) using  specific primers and probes (described in section “primers and 
probes”). Amplifications were performed as follows: 95° C for 5 minutes 
followed by 45 cycles at 95° C for 10 seconds, 58° C for 10 seconds and 72° C for 
20 seconds. Serial dilutions of a plasmid containing a monomeric genotype D 
HBV insert (Clonit Srl.) were used as quantification standards. The β – globin 
housekeeping gene was used to normalize the DNA samples. Amplifications were 
performed as follows: 95° C for 5 minutes followed by 45 cycles at 95° C for 10 
seconds, 58° C for 10 seconds and 72° C for 20 seconds. 
  
85 
 
HBV cccDNA QUANTIFICATION 
Cells were collected at the indicated times after transfection, resuspended in lysis 
buffer A (see above) and incubated 10 minutes at 4° C. Lysates were centrifuged 
1 minute at 13.000 rpm, pelleted nuclei resuspended in lysis buffer B (10 mM Tris 
– HCL, 10 mM EDTA, 150 mM NaCl, 0,5% SDS and 0.5 mg/ml proteine K) and 
incubated overnight at 37° C. Nucleic acids were purified by phenolchloroform 
(1:1) extraction and ethanol precipitation. 500 ng aliquots of each extracted DNA 
were treated for 45 minutes at 37° C with 10 U Plasmid safe DNAse I. DNAse 
was inactivated by incubating the reactions for 30 minutes at 70° C. Real – time 
PCR experiments were performed using specific primers (described in “primers 
and probes” section) in a Light Cycler instrument (Roche) using 20 ng of DNA. 
Amplification was performed as follows: 95° C for 10 minutes then 45 cycles of 
95° C for 10 seconds, 62° C for 10 seconds, and 72° C for 20 seconds. Serial 
dilutions of a plasmid containing a monomeric genotype D HBV insert (Clonit 
Srl.) were used as quantification standards. The β-globin housekeeping gene was 
used to normalize the DNA samples. Amplifications were performed as follows: 
95° C for 5 minutes followed by  45 cycles at 95° C for 10 seconds, 58° C for 10 
seconds and 72° C for 20 seconds. 
HBV RNAs AND CELLULAR mRNA EXTRACTION  
Total RNA was extracted from cells using the TRIzol reagent as recommended by 
the manufacturer. 4 µg of the RNA samples were treated with 1 U of RQ1 RNase 
– Free DNase for 60 minutes at 37° C, the reaction  was stopped adding 1 µl of 
stop solution. RNA samples were stored until used. 
REVERSE TRANSCRIPTION  
2 µg of DNase – treated RNA was reverse transcribed and amplified by Maxima 
H minus first strand cDNA synthesis kit as recommended by the manufacturer. 
The reaction was done as follows: incubation for 10  min at 25° C followed by 30 
min at 50° C. The reaction was terminate by heating at 85° C for 5 min. Then 1 µl 
86 
 
of each cDNA was quantified by real – time PCR analysis in a Light Cycler 
instrument (Roche) using the pgRNA specific primers and probes (described in 
section “primers and probes”). The actin housekeeping gene Light Cycler set was 
used to normalize the RNA samples.  
HBV RNAs ANALYSIS 
2 µl of each cDNA were quantified by real – time PCR analysis. The pgRNA was 
amplified with specific primers and probes (see above). The house – keeping gene 
ACTIN was use to normalized the RNA samples and was amplified with specific 
probes (see above). The reaction was performed as follows: 95° C for 10  minutes 
then 45 cycles of 95° C for 10 seconds, 62° C for 10 seconds, and 72° C for 20 
seconds. 
MTT ASSAY 
The cytotoxicity of epigenetic compounds in replicating HepAD38 cells was 
measured using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) assay. The cells were incubated for 48 h with HAP – 12 and AT – 
130 respectively at 1 and 5 µM final concentration in duplicate in a 6-well plate 
together with the respective control treatments (cells incubated with 2 µM 
doxorubicin (Sigma) only). The cells were then incubated with the MTT substrate 
(5 mg/mL in 0.1 M phosphate buffered saline (PBS) (GIBCO Life Technologies) 
for 4 h. Thereafter all supernatants were sucked, and DMSO (1 mL) was added to 
the wells. Finally the optical density was measured at 570 nm with a 
spectrophotometer (DU 530, Beckmann coulter). The data was translated to 
percentage cell viability. 
FLOW CYTOMETRIC ANALYSIS 
Flow cytometric analysis of the cell cycle, FACS analysis, was performed as 
described below: after 48 h incubation with DMSO (NT cells), 1 and 5 µM HAP – 
12 and AT – 130 treatments and 50 µM cisplatin (Sigma) (positive control) cells 
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were washed with PBS and incubated with 0.25 % trypsin-EDTA (GIBCO Life 
Technologies) for 10 min at 37° C. Afterwards, cells were centrifuged and washed 
twice in PBS, fixed in ice-cold 70% ethanol and incubed 2 h at 4° C. The cells 
were centrifuged, washed twice in PBS and stained with a freshly made solution 
containing 50 µg/mL propidium iodide (PI) (Life technologies), 0.1% Triton x-
100 (Sigma) and 40 µg/mL ribonuclease A (Sigma) in PBS. All samples were 
incubated for 30 min at room temperature in the dark. The percentages of cell 
cycle distribution were evaluated by PI staining by analytical DNA flow 
cytometer (Accuri C6, BD Biosciences) and data analysis was performed 
employing BD Accuri TM C6 software. 
IMMUNOBLOTTING 
PIERCE kit NE - PER® Nuclear and Cytoplasmic Extraction Reagents enable 
stepwise separation and preparation of cytoplasmic and nuclear extracts from 
mammalian cultured cells. HepAD38 pellet cells were resuspended and lysed in 
500 µl of ice-cold CER I plus protease inhibitor cocktail (PIC) vortex on the 
highest setting 15 sec and leave 10 min on ice, than add 27,5 µl ice-cold CER II to 
the tube, vortex on the highest setting 5 sec and incubate on ice for1 min. The 
nuclei were separated by centrifuge 13.000 rpm for 10 min at 4° C. Immediatley 
transfer the supernatant (Cytoplasmic extract) fraction to a clean pre-chilled tube. 
After the nuclei were lysed in 250 µl of ice-cold NER plus PIC, vortex on the 
highest setting for 15 sec than return the sample to ice and continue vortexing for 
15 sec every 10 min, for a total of 40 min. The proteins nuclear extract was 
separated by centrifuge 13.000 rpm for 10 min at 4° C and immediatley transfer 
the supernatant (Nuclear extract) to a clean pre – chilled tube. Protein 
concentration was determined by the BCA protein assay reagent. Protein lysates 
were transfered to a nitrocellulose membrane and incubated with CORE, LAMIN 
– B and ACTIN antibodies. 
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CHROMATIN IMMUNOPRECIPITATION ASSAY (ChIP) 
Cells were resuspended in 1 ml of ChIP lysis buffer (50 mM TrisHCL pH 8; 0,5% 
NP40; 1 mM EDTA; and 100 mM NaCL) and incubated 10 minutes at 4° C. The 
lysate was centrifuged at 13.000 rpm for 2 minutes to pellet the nuclei. The 
supernatant was removed and the nuclei were fixed in 1% formaldehyde for 30  
minutes at 4° C. Isolated cross – linked nuclei were extract with a 20 mM Tris pH 
8, 3 mM MgCl2, 20 mM KCl buffer containing protease inhibitors, pelleted by 
microcentrifugation and lysed by incubation in SDS lysis buffer (1% SDS, 10 mM 
EDTA, 50 mM Tris – chloride  pH 8.1), containing protease inhibitors. The 
resulting chromatin solution was sonicated for 5 pulses of 45 seconds at 80% 
power to generate 300 – 1000 bp DNA fragments using a BioRuptor sonicator 
(Diagenode, Inc). After microcentrifugation, the supernatant was diluited 1:10 in a 
dilution buffer (0.01% sodium dodecyl sulfate, 1.1% Triton X – 100 , 1.2  mM 
EDTA, 16.7 mM Tris – chloride pH 8.1, 167 mM NaCl, containing protease 
inhibitors), precleared with blocked protein G plus (Pierce), and divided into 
aliquots. The chromatin was then subjected to immunoprecipitation for 14 – 16  
hours at 4° C using antibodies specific to: HBc,  HBx, H4, AcH3 and AcH4. 
Immunoprecipitations with non specific immunoglobulins were included in each 
experiment as a negative control. After the reverse cross – linking, 
immunoprecipitated chromatin was purified by phenol/chloroform (1:1) extraction 
and ethanol precipitation. Chipped DNA was analyzed by real – time  PCR using 
specific cccDNA primers and probes, promoters of EZH2, SRC, E2F1, IL29, IL6, 
GAPDH and TP53 specific primers.  
FISH ASSAY 
12 day HBV – infected and HAP – 12 (1 µM) treated NTCP – Hepg2 cells were 
fixed with paraformaldehyde 4% in PBS 1x for 20 minutes at 4° C, then washed 
with PBS 1x three times and ultimately leaved in Et – OH 70% at 4° C. 500 ng of 
HBV genotype D linear genome labeled probe were precipitated in 17,5 γ of 
COT1 (1 mg/mL), 30 γ of salmon sperm DNA (10 mg/mL), NaAc 3 M pH 5,5 
1/10 V and 3 V 100% EtOH for each microscope slide. The cells were incubated 
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for 1 h at -80° C and then they were centrifugated  for half an hour 13000 rpm at 
4° C; wash the pellet two times with1 mL EtOH 70%. The pellet was resuspended 
in 6 µl (Formamide 50%; SSC 2x; Dextransulphate 10%) hybridation solution. 
Cells were pre – treated in Triton 0,3% PBS for 10 minutes at room temperature. 
After washing in PBS 1x three times cells were incubated in glycerole 20% PBS 
for 20 min and then they were incubated in glycerole 50% PBS solution overnight 
at -20° C.  
Microscope slides were equilibrated for 20 minutes at room temperature, 
incubated with glycerole 20% in PBS solution for 20 minutes and ice – cold 
freezed; the cells alternately were washed three times with PBS 1x and incubated 
with a diluition 1:100 of RNase A (10 mg/mL) in PBS for 1h at 37° C, with HCl 
0,1M/H2O for 30 minutes at room temperature and with Triton 0,3%/PBS for 20 
minutes at room temperature. Microscope slides were washed at least three times 
in PBS then one time in SSC 2x solution. Incubate the slides with the pre – 
hybridation solution at least 30 minutes at room temperature. After that the slides 
were incubated with Et – OH 70, 90 and 100% for 3 minutes each. The containing 
precipitated probe hybridation solution was applied on dried slides. Finally the 
slides were placed at 78° C for 4,5 minutes and they were incubated  overnight at 
37° C. Wash two times the slides with warm SSC 2x for 5 minutes at 37° C, one 
time with SSC 1x and one time with SSC 4x 5 minutes at room temperature. 
Slides were equilibrated in PBS 1x, they were fixed with PFA 4% 5 minutes at 
room temperature. Before incubation of slides with diluited 1:300 anti – dig cy3 
BSA 4% for 45 minutes wash them one time with PBS 1x and one time with SSC 
4X for 5 minutes at room temperature. To visualize nuclei cells were incubated 
with DAPI for 4 minutes. The final observation was obtained with an A1R+ 
Nikon confocal microscope.      
90 
 
 
RESULTS 
STEP I 
cccDNA CHROMATINIZATION AND HBc RECRUITMENT 
ARE EARLY EVENTS  
Several evidence support the notation that cccDNA bound histones. As shown in 
previous study (Bock et al., 2001), Cp interact with histones and bind the nuclear 
cccDNA. Using the cccDNA ChIP assay, that couples a classical chromatin 
immunoprecipitation step with a cccDNA – specific real time PCR to selectively 
detect the immunoprecipitation of cccDNA – bound histone and non – histone 
proteins. We previously showed that cccDNA transcriptional activity and HBV 
replication are controlled by the acetilation status of cccDNA – bound H3 and H4 
histones (Pollicino et al., 2006). In previuses work we have shown the regulatory 
protein HBx is recruited onto the cccDNA minichromosome in HBV – replicating 
cells (Belloni et al., 2009) and is required for both cccDNA transcription and 
HBV replication in the context of a natural HBV infection (Lucifora et al., 2011). 
In the absence of HBx, cccDNA – bound  histones are hypoacetylated, and the 
cccDNA transcribes significantly less pgRNA (Belloni et al., 2009). 
 
Firstly, to investigate when Cp is recruited on cccDNA and when cccDNA 
chromatinization begins, we performed a kinetics of HBV replication a cccDNA 
ChIP assay in infected NTCP – HepG2 cells with HBV MOI 500. We took 
advantage of an anti-HBc, anti-HBx, anti-H4 histone, a marker of 
chromatinization and an anti-acetylated-Lys9 of Histone 3, a marker of 
transcriptional activation. As shown in Figure 18A, already after 2 hours of 
infection it presents an enrichment of the cccDNA associated with the Cp, as in 
the case of the immunoprecipitate with anti-H4, whereas we observed, be 
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expected, an enrichment of cccDNA only after 4 – 8 hours in immunoprecipitates 
anti-HBx and anti-AcH4. To confirm this result we performed a similar kinetics 
of HBV replication cccDNA ChIP assay in infected PHHs with HBV MOI 200, 
we hybridized with an anti-HBc, we have shown that cccDNA accumulation was 
already in 2 hours Figure 18B.   
 
These results indicate that cccDNA chromatinization and HBc recruitment onto 
the cccDNA occur early post – infection in both NTCP – HepG2 cells and PHHs 
Figure 18B. 
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Figure 18: cccDNA chomatinization and HBc recruitment are early events.  
(A) Cross – linked chromatin is extracted from HBV – infected NTCP – HepG2 cells, 
kinetic quantitative evaluation of HBc, HBx, H4 and AcH3 bound cccDNA was 
performed by real time PCR on the immunoprecipitation as detailed in the Matirials and 
Metods section and expressed as cccDNA molecules. (B) Cross – linked chromatin is 
extracted from HBV – infected PHHs, kinetic quantitative evaluation of HBc was 
performed by real time PCR on the immunoprecipitation and expressed as cccDNA 
molecules. 
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HBc BINDS TO THE PROMOTERS OF CELLULAR GENES 
As mentioned in a previous study (Guo et al., 2012) HBc interacts with several 
promoters of cellular genes implicate different kind of regulatory pathway. Guo 
and colleagues performed ChIP – on – chip analysis with the NimbleGen HG18 
RefSeq Promoter Microarray consisting of 18028 of the best defined human 
transcript – associated promoters. Hepatocytes infected with HBV and expressing 
HBV core protein were isolated from CHB patients, immunoprecipitated with 
HBc antibody, and investigated to determine the genome – wide profile of bound 
host gene promoters. IgG pre – incubated with 100 – fold excess HBc antibody 
was used as a negative control, and immunoprecipitation of hepatocyte cells from 
healthy individuals was used as a blank control. In total, 3100 HBc – 
immunoprecipitated host promoter regions were found to be enriched by at least 2 
– fold in HBc – infected tissues compared to the blank controls (p  <  0.05). The 
GO analysis is a powerful tool by which the 3100 genes associated with the 
immunoprecipitated promoters may be correlated with biological processes or 
known protein functions. The 3100 genes were found to represent 55 pathways of 
the KEGG, according to the molecular interactions, reactions, and relations of the 
genes. They observed a further enrichment for pathways involved in tumor 
pathogenesis (Guo et al., 2012).  
 
In order to verify the reliability of the ChIP – on – chip results, we performed 
anti-HBc ChIP assay in Tet – released HepAD38 cells, HBV – infected NTCP – 
HepG2 cells and PHHs and we analyzed by TaqMan real time PCR using gene 
specific primers. We decided to investigate the genes those we found to be 
associated with HBV infection stages and we confirmed Cp bindings to the 
regulatory regions of the EZH2 histon methyl – transferase, cSRC proto – 
oncogene, that has been also shown to potentiate HBV replication, the E2F1 
transcription factor and cell cycle regulator and the IL29/lamda3 interferon, 
whereas the IL6 and GAPDH promoters were consistently not enriched and 
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served as negative controls. Figure 19 shows the results obtained from ChIP on 
PHHs, similar result obtained in Tet – off HepAD38 cells HBV – infected NTCP 
– HepG2 cells.  
 
The above results suggested that HBV core protein can bind to host gene 
promoters, especially those involved in HCC pathogenesis. 
 
 
 
 
 
 
 
Figure 19: HBc binds on the cellular gene promoters. Cross – linked chromatin is 
extracted from HBV – infected PHHs after 6 days from the infection ChIP assay was 
performed with anti-HBc antibodies. Immunoprecipitated chromatin samples were 
analyzed by TaqMan real time PCR using c-SRC, EZH2, IL29 and E2F1 promoters 
specific primers. Results are expressed as a percentage of input. Data (mean ±SD) from 3 
indipendent experiments are shown. 
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STEP II 
CORE PROTEIN AND ANTI – CAPSID DRUGS HAP – 12 AND 
AT – 130  
The viral capsid is formed by the HBc antigen, a small protein of 183 – 
185 aminoacids. Two protein domains with specific functions can be 
distinguished: the N – terminal  domain (NTD) and the C – terminal domain 
(CTD) (Chain and Myers, 2005). The NTD is involved in the formation of core 
dimers and in their self – assembly into capsids. The core protein (Cp) 
homodimers assembles in ichosaedrical capsids with a T=3 ot T=4 symmetry via 
oligomerization (Crowther et al., 1994). In vitro HBV assembly is nucleated by a 
trimer of dimers and proceeds by the addition of individual dimeric subunits. 
Empty capsids assemble at a rate that is a function of protein concentration and 
ionic strength (Zlotnick et al., 1999) The CTD domain is involved in pgRNA 
incapsidation and DNA replication (Gallina et al., 1989). A basic sequence mostly 
composed of arginines and serines undergoes phosphorylation and lead to the 
interaction between capsid and pgRNA or viral DNA (Nassal et al., 1990). The 
phosphorylation state of the core protein is associated with nucleocapsid 
maturation (Perlman et al., 2005). Only mature capsids can interact with envelop 
proteins (Dryden et al., 2006). Moreover core proteins have been shown to 
interact with histones and to bind the nuclear cccDNA, possibly contributing to 
the regulation of cccDNA function and the maintenance of the cccDNA stability 
(Bock et al., 2001); (Pollicino et al., 2006); (Guo et al., 2011). 
A molecule that modulates capsid assembly could interfere with the geometry of 
core protein interaction, packaging viral nucleic acid, and the stability of newly 
assembled virions (Zlotnick et al., 1999). Recently, capsid assembly has also been 
targeted in other viral systems, including HIV and HCV (Kota et al., 2010). A 
number of HBV assembly effectors have been investigated (Bourne et al., 2006); 
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(Stray et al., 2005). Phenyl – propenamide derivate AT – 130 and 
Heteroaryldihydropyrimidines (HAPs) are two new class of antivirals inhibiting 
HBV replication in vitro and in vivo (Deres et al., 2003); (Stray et al., 2005). AT 
– 130 increase capsid assembly reaction rate, interfere with HBV RNA packaging 
and to the formation of apparently normal empty capsids (Katen et al., 2010). 
HAP – 12 have been shown to enhance the rate and the extent of core protein 
assembly over a broad concentration range and to act as allosteric effectors to 
induce an assembly – active state or, at high concentration, stabilize preferentially 
non – capsid polymers of Cp (Katen et al., 2010); (Zlotnick et al., 1999).  
The antiviral activity was not related to the formation of polymer or intermediate 
structure. Normal capsid assembly is characterized by slow nucleation rate and 
weak pairwise dimer – dimer association energy. Therefore, changing either the 
strength or rate of association will affect the capsid production. Among others 
HAPs, HAP – 12 showed the strongest antiviral activity and also the greatest 
kinetic and thermodynamic effects on capsid assembly. Figure 20 shows the 
kinetic of the HAP – 12 activity. 
 
 
 
 
Figure 20: enhance the rate and the extent of core protein (Cp) assembly over a broad 
concentration range and to act as allosteric effectors to induce an assembly – active state 
or, at high concentration, stabilize preferentially non – capsid polymers of Cp.  
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CHARACTERIZATION OF HAP – 12 AND AT – 130 AND 
ACTIVITY  
HAP – 12 AND AT – 130 DO NOT AFFECT CELL VIABILITY AND 
CELL CYCLE PROGRESSION 
First of all we characterized core – inhibitors. We tested the cytotoxicity of HAP – 
12 and AT – 130 compounds in HepAD38 inducible system.  
 
We first performed a MTT assay on HepAD38 cells treated with anti – capsid 
HAP – 12 and AT – 130 respectively 1 and 5 µM concentration for 6 days. The 
graph in Figure 21B shows the fraction of living cells in HepAD38 samples 
treated with the anti – capsid is not significantly different from the untreated 
sample, meaning that the tested core – inhibitors drugs do not affect cell viability.  
 
We then performed a FACS analysis Figure 21A using HepAD38 cells treated 
with HAP – 12 and AT – 130 respectively 1 and 5 µM for 6 days. The fraction of 
cell populations in G1, G2/M, S and sub-G1 phase in treated cells is not 
significantly different from the control, showing that the tested anti – capsid 
compounds do not alter the cell cycle progression. 
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Figure 21: Effect of core – inhibitors on cycle progresson and cell viability. 
HepAD38 cells treated with anti – capsid HAP – 12 and AT – 130 respectively 1 and 5 
µM concentration for 6 days. (A) Cell cycle analysis using propidium iodide (PI) staining 
and flow cytometry. HepAD38 cells were treated with DMSO (NT) 5 µM or HAP – 12 
and AT – 130 drugs at the respectively concentration 1 and 5 µM for 48h. As control of 
apoptosis  cells were treated with 50 µM cisplatin for 48h. Bars denote percentage of sub 
– diploid cells. Data from one representative experiment out of three are shown. (B) 
HepAD38 cells were incubated with HAP – 12 and AT – 130 drugs at the respectively 
concentration 1 and 5 µM or with DMSO (NT) 5 µM. As positive control HepAD38 cells 
were treated with 500 ng/mL doxorubicin. MTT assay was performed after 48h. the 
results are pictured as percentage of number of alive cells compared with the untreated 
sample (100% of living cells) and represent the mean ± SD of three independent 
experiments.  
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CORE – INHIBITORS HAVE A DIFFERENT EFFECT ON HBc 
EXPRESSION LEVELS 
Secondly for further characterization we focused to evaluate the effect of core – 
inhibitors on HBc expression. HepAD38 cells were induced and treated with HAP 
– 12 and AT – 130 (respectively 1 and 5 µM), than we harvested the cells 10 days 
after treatment and we extracted the nuclear and cytoplasic fractions. We 
performed a Western Blot analysys and we found that HAP – 12 treatment lowers 
HBc protein levels in the cytoplasm, whereas AT – 130 does not have any effect 
on HBc protein levels, neither in the nucleus or in cytoplasm Figure 22. 
 
 
 
 
Figure 22: Effect of core – inhibitors on Cp expression. HepAD38 cells were induced 
and treated with HAP – 12 and AT – 130 (respectively 1 and 5 µM) for 10 days. Nuclear 
and cytoplasmatic proteins were extracted and analyzed by western blot analysis. 30 µg 
of nuclear and cytoplasmatic proteins were analyzed for HBc and lamin – B and actin as 
control. 
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HAP – 12 AND AT – 130 ANTIVIRAL ACTIVITY IN HepAD38 
CELLS 
HAP – 12 AND AT – 130 PREVENT CAPSID RECYCLING AND 
cccDNA ACCUMULATION IN HepAD38 CELLS 
To investigate the impact of anti – capsid HAP – 12 and AT – 130 on cccDNA 
formation, HepAD38 cells were induced and treated with HAP – 12 and AT – 130 
(1 and 5 µM) for 10 days. To characterize the effect of core – inhibitors on viral 
replication total and viral RNAs, HBV DNA and cccDNA were extracted and 
analyzed by real time PCR using specific primers and probes. As shown in Figure 
23 anti – capsid drugs HAP – 12 and AT – 130 lead strong suppression of HBV 
replication that is accompanied by a 50% reduction of pgRNA transcription and 
by a 95% decrease in cccDNA levels. 
  
These results suggest that core – inhibitors affect HBV replication and prevent 
cccDNA accumulation by blocking the recycling of mature core particles into the 
nucleus. 
  
 
 
 
Figure 23: Core – inhibitors affects HBV DNA, pgRNA and cccDNA levels. Capsid 
associated (Cp) HBV DNA, pgRNA and cccDNA were extracted from stably replicating 
HepAD38 cells treated with HAP – 12 and AT – 130 for 10 days. The pgRNA, cccDNA 
and HBC DNA were extracted and quantificated by real time PCR using selective 
primers and probes. Results are expressed as fold induction (mean ± SD) from three 
independent experiments.    
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HAP – 12 REDUCES pgRNA TRANSCRIPTION FROM THE 
cccDNA IN HepAD38 CELLS 
Previous experiment did not show a strong reduction of the pgRNA transcription 
as much as for HBV replication and cccDNA levels. 
 
To better investigate if core – inhibitor HAP – 12 impacts on the pgRNA 
transcription, HepAD38 cells were inhibited to stably replicate reintroducing 
tetracycline in the medium, eliminating the contribution of the integrated HBV 
genome in HBV DNA and pgRNA; in these conditions the pool of cccDNA 
accumulated in the first phase of stably replication thanks to the recycling of 
mature capsids to the nucleus is the only source of pgRNA. Thus secondly 
HepAD38 cultured in presence of tetracycline were treated for 6 days whit HAP – 
12 drugs and harvested to isolate pgRNA; as show by real time PCR assay in 
Figure 24, in agreement with previous experiment, HAP – 12, without 
interference of integrated HBV genome, leads to a strong suppression of HBV 
replication and  reduction of pgRNA transcription.  
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Figure 24: pgRNA transcription was analyzed in HepAD38 shutted down for HBV DNA 
integrated expression reintroducing Tetracycline in the mudium as described in Materials 
and Methods section. After allowing the cells to accumulate HBV intermediates in the 
nucleus and in the cytoplasm for 6 days with HAP – 12 drug, the pgRNA was extracted 
and quantificated by real time PCR using selective primers and probes and actin primers. 
Results are expressed as fold induction (mean ± SD) from three independent experiments.    
 
 
 
 
 
 
 
 
 
 
 
103 
 
STEP III 
CHARACTERIZATION OF HAP – 12 ANTIVIRAL ACTIVITY 
IN HBV – INFECTED NTCP – HepG2 CELLS AND PHH 
HAP – 12 AFFECTS HBV DNA, pgRNA AND cccDNA LEVELS IN 
NTCP – HepG2 INFECTED CELLS 
To test the effect of HAP – 12 antiviral in modulating HBV replication and 
transcription, in a context of complete HBV infection cycle, we used NTCP – 
HepG2 cells. Recently, the sodium taurocholate co – transporting polypeptide 
(NTCP) membrane transporter was reported as an HBV entry receptor (Yan et al., 
2012); (Ni et al., 2014). The NTCP – HepG2 cells can be efficiently infected with 
HBV and recapitulate all the steps of the viral cycle (see material and methods for 
procedure). 
 
We infected NTCP – HepG2 cells and treated them with HAP – 12 (1 µM) for 12 
days.  
To characterize the effect of core – inhibitors on viral replication total and viral 
RNAs, HBV DNA and cccDNA were extracted and analyzed by real time PCR 
using specific primers and probes. In agreement with the results obtained in 
HepAD38 a HAP – 12 treatment started at the time of infection strongly 
suppresses of HBV replication, reduces pgRNA transcription and leads to a sharp 
reduction of cccDNA levels Figure 25.  
 
These results indicate that in NTCP – HepG2 infected cells HAP – 12 efficiently 
inhibits HBV replication, pgRNA transcription and a drastic reduction of cccDNA 
formation, suggesting an important role of Cp for rcDNA release into the nucleus, 
conversion of rcDNA into cccDNA or cccDNA chromatinization. 
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Figure 25: Core – inhibitors affects HBV DNA, pgRNA and cccDNA levels. cccDNA, 
pgRNA and capsid associated (Cp) were axtracted from NTCP – HepG2 treated with 
HAP – 12 for 12 days. The pgRNA, cccDNA and HBC DNA were extracted and 
quantificated by real time PCR using selective primers and probes. Results are expressed 
as fold induction (mean ± SD) from three independent experiments.    
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HAP – 12 REDUCES cccDNA TRANSCRIPTION AND HBV 
REPLICATION IN HBV – INFECTED NTCP – HepG2 CELLS AND 
PHHs 
 
If HAP – 12 treatment is started at the time of HBV infection (NTCP – HepG2 
cells) or at the time of HBV induction (HepAD38 cells), the effect seen on 
cccDNA levels could be due to the inhibition of cccDNA formation by the anti – 
capsid compounds that prevents the establishment ot cccDNA pool rather than a 
direct “destabilizing” effect on existing cccDNA. 
   
To better investigate the HAP – 12 effects on cccDNA stability we also started to 
treat NTCP – HepG2 cells and PHHs after 10 days of infections, when cccDNA is 
accumulated in infected nuclei and cccDNA levels seem to be stable. As shown in 
Figure 26A-B, HAP – 12 treatment leads to a strong suppression of HBV 
replication and to a reduction of the 50% of pgRNA transcription, whereas no 
effect on cccDNA levels. These results suggest that the core – inhibitor blocks 
HBV replication and transcription, but HAP – 12 does not impact on cccDNA 
stability.  
 
The reduction in cccDNA levels we observed both in HBV induction HepAD38 
cells and in HBV – infected NTCP – HepG2 cells treated with HAP – 12 at the 
time of respectively induction or infection rather reflect a block of the drug on the 
formation of functional nucleocapsid and the block of the recycling of mature core 
particles in to the nucleus.  
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Figure 26: HAP – 12 does not impact on cccDNA stability. (A) cccDNA, pgRNA and 
capsid associated (Cp) were axtracted from NTCP – HepG2 cells treated with HAP – 12, 
after 10 days of HBV infection, for 6 days. (B) cccDNA, pgRNA and capsid associated 
(Cp) were axtracted from PHHs treated with HAP – 12, after 10 days of HBV infection, 
for 6 days. The pgRNA, cccDNA and HBC DNA from NTCP – HepG2 cells and PHHs 
were extracted and quantificated by real time PCR using selective primers and probes. 
Results are expressed as fold induction (mean ± SD) from three independent experiments. 
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HAP – 12 BLOCKS HBc RECRUITMENT ON THE cccDNA AND 
REDUCES cccDNA – BOUNDS HISTONES ACETILATION IN HBV 
INDUCTION HepAD38 AND HBV INFECTION NTCP – HepG2 
CELLS  
At this point we focused to understand how capsid – inhibitors inhibit HBV 
replication, prevent cccDNA accumulation and target cccDNA transcription. 
 
In order to understand whether HAP – 12 antiviral activity involves an epigenetic 
mechanism mediated by the suppression of cccDNA transcription, we performed 
two ChIP assays, respectively, in stably replicating HepAD38 cells treated for 10 
days and in HBV – infected NTCP – HepG2 cells treated for 6 days after 10 days 
of infection, with HAP – 12 (1 µM). As shown in Figure 27 A and B, in both 
induction and infection models, HAP – 12 decreases the relative amount 
acetylated H4 histone on the minichromosome, leading to a transcriptionally 
suppressed cccDNA. By ChIP assays we found, also, that HAP – 12 induces a 
strong reduction in Cp binding to the minichromosome Figure 27A-B. As show in 
Figure 22, HAP – 12 activity does not affect HBc protein levels in the nucleus.   
 
Altogether, these results support a model in which the reduction of HBV 
replication after HAP – 12 treatment is due to both the epigenetic inhibition of 
cccDNA transcriptional activity (and consequently a reduction of pgRNA levels) 
and to an inappropriate assembly of Cp.  
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Figure 27: HAP – 12 Inhibits pgRNA transcription by epigenetic mechanisms. (A) 
Chromatin from stably replicating HepAD38 cells treated and non treated with HAP – 12 
for 10 days was immunoprecipitated with anti-Acetylated H4 and anti-HBc antybodies; 
(B) Chromatin from HBV – infected NTCP – HepG2 cells treated and non treated with 
HAP – 12 for 6 days after 10 days of infection was immunoprecipitated with anti – 
Acetylated H4 and anti – HBc antybodies; Immunoprecipitated chromatin was analyzed 
by real time PCR with HBV cccDNA selective primers.      
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HBV cccDNA FISH 
To visualized nuclear cccDNA, we performed a DNA FISH using genotype D 
specific probe encompassing the whole HBV genome in HBV – infected NTCP – 
HepG2 cells treated with HAP – 12 immediately after infection for 12 days. As 
shown in Figure 28 in agreement with results previously obtained, cccDNA was 
detected in untreated cells nuclei, whereas, as expected, no signal was seen in the 
HAP – 12 treated infected cells nuclei, exactly as in the mock cells nuclei.  
 
 
 
 
 
 
Figure 28: cccDNA does not detect in HAP – 12 treated nuclei. DNA FISH assay 
cccDNA expressed in NTCP – HepG2 infected with HBV at 500 moi treated with HAP – 
12 at T0 post-infection for 12 days. DAPI staining, and their merged image are shown.   
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STEP IV 
IMPACT OF HAP – 12 ON Cp RECRUITMENT ONTO 
PROMOTERS IN TET – OFF HepAD38 AND HBV – 
INFECTED NTCP – HepG2 CELLS 
HAP – 12 TREATMENT BLOCKS HBc RECRUITMENT ON 
CELLULARE GENE PROMOTERS IN HBV INDUCTION HepAD38 
AND HBV INFECTION NTCP – HepG2 CELLS 
As seen before, in the recent work, Guo and colleagues have demonstrated that 
HBc bindings a large number of cellular gene promoters. Previously we have 
confirmed the results of Guo and we demonstrated that HBV core protein can 
bind to host gene promoters, especially those involved in HCC pathogenesis (see 
HBc binds to the promoters of cellular genes Figure 19). 
 
Finally, we investigated the effect of HAP – 12 capsid – inhibitor onto Cp 
recruitment on cellular gene promoters. To this aim we performed anti – HBc 
ChIP assays in tet released HepAD38 cells and HBV – infected NTCP – HepG2 
cells. We discovered that HAP – 12 treatment was able to block Cp recruitment to 
the regulatory regions of EZH2, cSRC, E2F1 and IL29/lamda3 in both tet – off 
HepAD38 and HBV – infected NTCP – HepG2 cells, wherase the TP53 and 
GAPDH promoters were consistently not enriched and served as negative controls 
Figure 29 A and B.   
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Figure 29: HAP12 blocks the binding of HBc to the cellular genes promoters.  
(A) Stably replicating HepAD38 cells treated and non treated with HAP – 12 for 10 days 
and chromatin was immunoprecipitated with specific HBc antibody. ChIPed DNA was 
analyzed by TaqMan real time PCR using c-SRC, EZH2, IL29 and E2F1 promoters 
specific primers. TP53 and GAPDH promoters were served as negative controls. Results 
are expressed as a percentage of input. Data (mean ±SD) from three indipendent 
experiments are shown. (B) Chromatin from HBV – infected NTCP – HepG2 cells 
treated and non treated with HAP – 12 for 6 days after 10 days of infection was 
immunoprecipitated with anti-HBc. ChIPed DNA was analyzed by TaqMan real time 
PCR using c-SRC, EZH2, IL29 and E2F1 promoters specific primers. GAPDH promoters 
was served as negative controls. Results are expressed as a percentage of input.    
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DISCUSSION 
The HBV nucleocapsid, that comprises the viral Cp assembled into the capsid 
proper, viral nucleic acids (pgRNA, converted ssDNA and than in dsDNA) and 
host, viral (DNA – Pol) proteins, represents an attractive target for anti – HBV 
therapy. It has been shown that the HBx regulatory protein is recruited onto the 
minichromosome cccDNA parallels the HBV replication. Results obtained in 
HBV mutant that does not express HBx show that p300 recruitment is severely 
impared, and cccDNA – bound histones era rapidly hypoacetylated, whereas the 
recruitment of the histones deacetylases hSIRT1 and HDAC1 is increased and 
occurs at earlier times (Belloni et al., 2009), supporting the notation of an 
epigenetic mechanism underlying the ability of HBx to control HBV replication. 
Similarly to HBx protein, Cp has been considerate to be an excellent target for 
antiviral therapy due to its critical roles in multiple steps of virus replication. 
Indeed, proper assembly of the capsid is critical for RNA packaging, reverse 
transcription and intracellular trafficking (core nuclear delivery, core nuclear 
recycling). Moreover Cp have been shown to interact with histones and to the 
nuclear cccDNA (Bock et al., 2001); (Pollicino et al., 2006); (Guo et al., 2011) 
Figure 30A. The results presented in my Thesis highlight the role of Cp, in the 
interaction with the cccDNA and cellular gene promoters, and the impact of a new 
class of antivirals that target the HBV capsid and inhibit HBV replication in vitro 
(Deres et al., 2003); (Stray et al., 2005). 
 
In the step I by ChIP assay it has been shown that cccDNA chromatinization and 
HBc recruitment onto cccDNA occur early post – HBV infection. Moreover we 
verified the reliability of the ChIP – on – ChIP results that Guo and colleagues 
obtained. We confirmed that Cp binds some cellular gene promoters, EZH2 histon 
methyl – tranferase, cSRC proto – oncogene, that has been also shown to 
potentiate HBV replication, the E2F1 transcription factor and cell cycle regulator, 
and the IL29/lamda3 interferon, that are associated with HBV infection stages and 
involved in the development of HCC. Indicating that HBc recruitment onto 
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cccDNA occur in early stages of infection and suggesting that HBV core protein 
can bind to host gene promoters, especially those involved in HCC pathogenesis, 
these results confirm Cp as an attractive new therapeutic specific target for HBV 
chronic infection. 
 
Several compound that target Cp and HBV capsid assembly have been shown to 
inhibit replication. In the step II we focused on two different classes of Cp 
assembly modulators. Heteroaryldihydropyrimidines (HAPs) have been shown to 
enhance the rate and extent of core protein assembly and to act as allosteric 
effectors to induce an assembly – active state (Stray et al., 2005). Whereas the 
effect of phenyl – propenamide on capsid formation is described as forming 
apparently normal capsid that lack generic material (Feld et al., 2007). It has been 
demonstrated, However, that AT – 130 behaves as an assembly and accelerator 
(Katen et al., 2010), increasing the rate of assembly and generating empty capsids.  
At first we characterized HAP – 12 and AT – 130 activity. MTT assay indicated 
that the tested core – inhibitors drugs do not affect cell viability, than FACS 
analysis, also, show that the tested anti – capsid compounds do not alter the cell 
cycle progression. Finally, by western blot it has been shown that HAP – 12 
treatment lowers HBc protein levels in the cytoplasm, whereas AT – 130 
treatment does not have any effect on Cp levels, neither in the nucleus or in 
cytoplasm.  
At a later time we focused HAP – 12 and AT – 130 antiviral activity in HepAD38 
cells. We observed that core – inhibitor compounds reduce pgRNA transcription 
from the cccDNA, prevent capsid recycling and cccDNA accumulation in this cell 
based HBV replication model. These results show that core – inhibitors affect 
HBV replication and prevent cccDNA accumulation by blocking the recycle of 
mature core particles into the nucleus, suggesting an important role of Cp for 
rcDNA release into the nucleus, conversion of rcDNA into cccDNA or cccDNA 
chromatinization.  
 
In the step III we better characterized HAP – 12 in HBV infection models and we 
proved that the reduction in cccDNA levels that we observed both in HBV 
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induction HepAD38 cells and in HBV – infected NTCP – HepG2 cells treated 
with HAP – 12 at the time of respectively induction or infection rather reflect a 
block of the drug on the formation of functional nucleocapsid and the block of the 
recycling of mature core particles in to the nucleus. Conversely, when HAP – 12 
treatment was started 10 days post – infection, when the cccDNA pool is 
established and stable in HBV – infected cells we observed very little or no effect 
on cccDNA levels, a significant reduction of cccDNA transcription and pgRNA 
levels together with a very strong inhibition of total HBV DNA and viral 
replication. ChIP assay indicated that HAP – 12 inhibitory effect is induced by 
decreasing the acetylated histon H4 binging to the microchromosome.    
  
Importantly, with the ChIP assays performed in the step IV we discovered that 
HAP – 12 treatment was able to blocks Cp recruitment on genes promoters. 
 
Altogether these results identify capsid – inhibitors as the first class “virus 
specific” compounds capable to target the cccDNA functions and potentially 
counteract Cp pathogenicity in infected hepatocytes (Figure 30).  
 
      
 
 
Figure 30: Core – inhibitors (HAP – 12, AT – 130) impact on Cp nuclear functions at 
multiple levels. Anti – capsid compounds block new cccDNA accumulation and they 
reduce viral RNAs transcription from an established cccDNA pool. HAP – 12 interferes 
with Cp recruitment onto minichromosome cccDNA and relevant host gene promoters. 
Figure modified from (Nassal, 2008).   
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